HERV-K Antibody Therapy
Humanized anti-HERV-K antibodies and CAR-T cells targeting HERV-K antigens address the lack of effective tumor-specific antigens in cancer therapy, enhancing tumor cell killing and inhibiting metastasis through combined immunotherapy approaches.
Patent Information
- Application Number
- JP2024516706
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-09-18
- Filing Date
- 2022-09-16
- Publication Date
- 2024-11-08
AI Technical Summary
Current cancer therapies lack effective tumor antigens that are highly expressed on tumor cells but absent from normal cells, limiting their efficacy, and there is a need for targeted cancer immunotherapy with minimal off-target effects.
Development of humanized anti-HERV-K antibodies and CAR-T cells targeting the HERV-K antigen, which is specifically expressed in various cancer types, including breast, lung, and prostate cancers, combined with checkpoint inhibitors and other therapeutic agents to enhance tumor cell killing and reduce metastasis.
The HERV-K targeted therapy induces apoptosis, suppresses cancer cell proliferation, reduces tumor viability, and inhibits metastasis, demonstrating improved treatment outcomes in preclinical models.
Smart Images

Figure 2024541175000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates generally to cancer antigens. [Background technology]
[0002] Human endogenous retroviruses (HERVs) are well known genomic repeats that are present in many copies within the genome. Approximately 8% of the human genome is of retroviral origin. See Lander et al. Nature. 409, 860-921 (2001). Due to the accumulation of genetic mutations, retroviruses usually lose their infectiousness. Their genes are mostly dormant and not expressed in normal adult human tissues, except in pathological conditions such as cancer.
[0003] HERV-K has a complete sequence that can express all the elements required for a replication-competent retrovirus, but remains silent in normal cells. Larsson, Kato, & Cohen, Current Topics Microbiol. Immunol., 148, 115-132 (1989); Ono, Yasunaga, Miyata, & Ushikubo, J. Virol. 60, 589-598 (1986). The present inventors and other researchers have reported that HERV-K expression is sometimes activated in tumors, and its envelope protein can be detected in several types of tumors and can be found at much higher levels than in normal tissues, as described below. See International Pat. Publ. WO 2010 / 138803 (Board of Regents, the University of Texas System); Wang-Johanning et al., Cancer Res., 77, Abstract nr LB-221 (2017); Johanning et al., Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci. Rep., 7, 41960 (2017); and Li et al., Clinical Cancer Research (2017). This association indicates that HERV-K is a good tumor-associated antigen and could be an ideal target for cancer immunotherapy. HERV-K is expressed in tumors and is absent in normal tissues, minimizing off-target effects.
[0004] An important consideration in the development of cancer therapeutics is the expression profile of tumor-associated antigens. HERV-K is transcriptionally active in cancer tissues and cell lines. The inventors specifically identified HERV proteins and sequences in cancer cell lines and patient tumors. The inventors observed expression of HERV-K, and in particular expression of HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. They also found that expression of HERV-K env transcripts in breast cancer is specifically associated with basal breast cancer, a highly aggressive subtype. See Johanning et al., Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci. Rep., 7, 41960 (2017).
[0005] Several diagnostic agents can be used as companion diagnostic agents for patient selection. One strategy targets endogenous viral antigens found only in cancer cells and not in normal tissues. We have found that both HERV-K RNAs (env or gag) and anti-HERV-K antibodies appear in the circulation of cancer patients.
[0006] Improved understanding of the tumor microenvironment in breast cancer is important for the design of rational and effective therapeutic approaches. One problem that has limited the success of therapeutic approaches against solid tumors is the lack of tumor antigens that are highly expressed by tumor cells but absent from normal cells.
[0007] We previously showed that HERV-K Env protein is commonly expressed on the surface of breast cancer cells. Wang-Johanning et al., J. Natl. Cancer Inst., 104, 189-210 (2012). Epithelial-mesenchymal transition (EMT) lowers infiltration of CD4 or CD8 T cells in some tumors. Chae et al., Science Reports, 8, 2918 (2018). HERV-K expression has been shown to induce epithelial-mesenchymal transition and enhance cell motility, both of which favor tumor dissemination. Lemaitre et al., PLoS Pathog., 13, e1006451 (2017). Overexpression of HERV-K leads to cancer initiation and contributes to cancer progression. Summary of the Invention
[0008] We found that checkpoint molecule levels in serum and tumor infiltrating lymphocytes (TILs) are highly correlated with HERV-K antibody titers, especially in patients with invasive breast cancer, such as invasive ductal carcinoma (IDC) or invasive breast cancer (IMC). The phenotypic and functional characteristics of tumor infiltrating lymphocytes in breast cancer are associated with HERV-K status. The combination of checkpoint inhibition and HERV-K antibody therapy should have better killing effect.
[0009] In a first embodiment, the present invention provides therapeutic humanized anti-HERV-K antibodies. The present invention also provides therapeutic humanized anti-HERV-K antibodies, DNA-encoded BiTe (DBiTE) or antibody-drug conjugates (ADC) of bispecific T cell-inducing antibodies (BiTE) against CD3 or CD8. Cancer cells overexpressing HERV-K are good targets for the anti-HERV-K humanized antibodies and antibody-drug conjugates of the present invention, because more antibodies can be bound per cell.
[0010] In a second embodiment, the present invention provides a bacterially produced humanized antibody clone (HUM1). The present invention also provides a mammalian cell produced humanized antibody (hu6H5). Both groups of antibodies bind to the recombinant HERV-K Env surface fusion protein (KSU) and antigens produced from lysates of MDA-MB-231 breast cancer cells. The mammalian cell produced hu6H5 was compared to our other forms of anti-HERV-K antibodies. The binding affinity of hu6H5 to the HERV-K antigen was similar to that of the murine antibody (m6H5), the chimeric antibody (cAb) and the humanized antibody (HUM1). The hu6H5 antibody induces cancer cells to undergo apoptosis, inhibits cancer cell proliferation and kills cancer cells expressing the HERV-K antigen. The hu6H5 antibody was shown to reduce tumor viability in mouse MDA-MB-231 xenografts and reduced cancer cell metastasis, particularly to the lungs and lymph nodes. Mice bearing human breast cancer that were treated with these humanized antibodies showed increased survival times compared to control mice that did not receive the antibody treatment.
[0011] In a third embodiment, the present invention provides a HERV-K env gene generated from a breast cancer patient as an oncogene, which can induce cancer cell proliferation, tumor growth, and metastasis to the lung and lymph nodes. Cells expressing HERV-K have been shown to have decreased expression of genes related to tumor suppression, including Caspase 3, Caspase 9, pRB, SIRT-1, and CIDEA. Cells expressing HERV-K have shown increased expression of tumorigenesis-related genes, including Ras, p-ERK, PP-38, and beta Catenin.
[0012] In a fourth embodiment, the present invention provides BiTEs against T cell CD3 or CD8 and tumor associated antigen HERV-K. The inventors have generated such BiTEs, which contain either CD3 or CD8 and an antibody targeting HERV-K (VL-VH 6H5scFv---VH-VLhuCD3 or CD8+c-myc+FLAG) or (VL-VH hu6H5scFv---VH-VLhuCD3 or huCD8+c-myc+FLAG). The FLAG tag is a peptide recognized by the antibody (DYKDDDDK) (SEQ ID NO: 38), and the Myc tag is a short peptide recognized by the antibody (EQKLISEEDL) (SEQ ID NO: 39).
[0013] In a fifth embodiment, the present invention provides T cells expressing lentiviral CAR expression vectors, which carry humanized or fully human HERV-K scFv. See Figure 1. These T cells effectively lyse and kill tumor cells from several cancers. The humanized K-CAR expressed from the lentiviral vector is a pan-cancer CAR-T.
[0014] In a sixth embodiment, the present invention provides a humanized single chain variable region (scFv) antibody. The antibody can bind to an antigen made from recombinant HERV-K Env surface fusion protein (KSU) and lysate from MDA-MB-231 breast cancer cells. The CAR made from this humanized scFv can be cloned into a lentiviral vector. This recombinant vector can be used in combination with other therapies, including but not limited to K-CAR T cells and checkpoint inhibitors, inflammatory cytokines (e.g., interleukin (IL)-12 and IL-18), oncolytic viruses, and kinase inhibitors. Kinase inhibitors include but are not limited to p-RSK and p-ERK.
[0015] In a seventh embodiment, the present invention provides HERV-K staining, which in many cases overlaps with the staining of the serum tumor marker CK. HERV-K can be a CTC marker and a target for HERV-K antibody therapy.
[0016] In the eighth embodiment, the present invention provides HERV-K as a stem cell marker. Targeting HERV-K can inhibit tumor progression by slowing or blocking the growth of cancer stem cells. Targeting HERV-K with circulating therapeutic antibodies or other therapeutic agents can also kill CTCs and block the metastasis of these circulating cells to distant sites.
[0017] In a ninth embodiment, the present invention provides that forced overexpression of HERV-K by chemicals (e.g., Poly I:C treatment) or hypomethylation of the LTR (e.g., by 5-Aza) that induce expression of HERV-K through the innate immune response, causing cancer cells to increase production of the target, thereby making the cancer cells more susceptible to targeted therapies, including targeted immunotherapy.
[0018] In a tenth embodiment, the present invention improves the in vivo enrichment technique in SCID / beige mice (IVE: approximately 20-fold enrichment), allowing for rapid expansion and activation of B cells. This improved technique can generate many antigen-specific plasmablasts. For tumor-bearing donors with higher titer antibodies, the improved technique uses a protocol in humanized mice (HM) or human tumor mice (HTM) instead of standard SCID / beige mice. For normal donors without cancer and without memory B cells, the improved technique uses a modified protocol: mice are treated with a cytokine cocktail (days 1, 7, 14). The mice are then boosted with antigen on days 14 and 21. Serum is collected from the mice and tested for binding affinity by ELISA. After an increase in antibody titer is detected, spleens are collected, analyzed, and used for hybridoma generation. Higher antibody titers were detected in mice using the in vivo enrichment protocol.
[0019] In an eleventh embodiment, the present invention provides a method for determining cells that can not only produce antibodies but also bind antigens and kill cancer cells, which efficiently stimulates CD40-B cells to proliferate into large numbers of highly pure (>90%) cells and induce their secretion of antibodies.
[0020] In a twelfth embodiment, the invention provides a method in which after incubation of the treated B cells, the glass coverslips are washed, labeled with fluorescent anti-human IgG antibodies, and read using microintaglio techniques to detect discrete dots corresponding to the secretion of antigen-specific antibodies by single B cells.
[0021] In a thirteenth embodiment, the present invention provides for the development of a platform to determine the binding kinetics and cell-cell interactions of individual cells in microwell plates.
[0022] In the fourteenth embodiment, the present invention notably provides a significantly enhanced expression of six circulating immune checkpoint proteins in the plasma of breast cancer patients. The present invention also provides a significant reduction in immune checkpoint protein levels in patients before surgery and 6 or 18 months after surgery. There is a clear correlation between soluble checkpoint protein molecule levels and HERV-K antibody titers induced by HERV-K expression in tumors. HERV-K antibody titers can affect immune checkpoint protein levels in breast cancer. Thus, HERV-K expression can control the immune response of breast cancer patients.
[0023] In another aspect, these findings collectively indicate that the HERV-K immunosuppressive domain (ISD) is an as yet unrecognized immune checkpoint on cancer cells, similar to the PD-L1 immune checkpoint. In a fifteenth embodiment, the present invention provides that inhibiting the ISD of HERV-K with immune checkpoint inhibitors (including but not limited to monoclonal antibodies and drugs that target the HERV-K ISD) is a cancer immunomodulatory therapy, allowing T cells to continue functioning and mount an immune response against cancer, boost existing responses, and promote elimination of cancer cells.
[0024] In a sixteenth embodiment, the present invention provides humanized and fully human (hTab) antibodies targeting HERV-K. These antibodies enhance the efficiency of checkpoint inhibitor antibody therapy. Effective cancer combination therapies include, but are not limited to, combinations of the following: (a) HERV-K humanized or hTAb (1.5 mg / kg), (b) K-CAR, (c) K-BiTE, (d) HERV-K shRNAs or CRISPR / Cas9 genome editing technology to knock down HERV-K gene expression, (e) or preventative or therapeutic HERV-K vaccines (including full-length, truncated HERV-K Env proteins and HERV-K Env peptides). Effective cancer combination therapies include full-length, truncated HERV-K Env proteins and HERV-K Env peptides, in combination with other elements, including, but not limited to: (a) anti-ICP antibodies, (b) cancer chemotherapy, (c) 5-azacytidine, 5-aza-2'-deoxycytidine, or other epigenetic modifiers (e.g., DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi)), (d) EMT inhibitors, (e) inhibitors of cell migration or invasion, (f) induction of S or G2 phase cell cycle arrest, (g) inhibitors of the PI3K / AKT / mTOR or MAPK / ERK signaling pathways, or (f) signaling to HIF1α.
[0025] In a seventeenth embodiment, the present invention provides a humanized antibody targeting HERV-K that can be used in antibody drug conjugates to deliver drugs to cancer cells and tumors.
[0026] In an eighteenth embodiment, the present invention provides an antibody targeting HERV-K that may be used for tumor imaging.
[0027] In a nineteenth embodiment, the present invention provides a new CAR that uses the hu6H5 scFv.
[0028] In a twentieth embodiment, the present invention provides new BITEs that use hu6H5 scFv, including CD3 BiTEs and CD8 BiTEs. [Brief description of the drawings]
[0029] FIG. 1 is a schematic diagram of lentiviral CAR expression vectors (pWPT-GFP vector with psPAX2 and pMD2g) carrying humanized or fully human HERV-K scFv.
[0030] Figure 2 shows an ELISA used to compare binding of chimeric 6H5, HUM1 (produced from bacteria), and the new hu6H5 (a new humanized anti-HERV-K antibody produced from mammalian cells) to the HERV-K env target at 1000, 1:1000 dilution; 2000, 1:2000 dilution; 4000, 1:4000 dilution; 8000, 1:8000 dilution.
[0031] Figure 3 shows the MTS assay used to determine the inhibition of hu6H5-treated cell proliferation. A significant decrease in cell proliferation was observed in cells treated with either 6H5 antibody (human or mouse). The inhibition was more pronounced in 231K cells expressing high levels of HERV-K than in 231C cells, which do not express higher levels of HERV-K. 231K cells are MDA-MB-231 human breast cancer cells stably transduced with HERV-K full-length viral envelope gene protein by retroviral vector and were evaluated in comparison with control non-transduced cells (231C) for cell proliferation, cell killing, and apoptosis.
[0032] Figure 4 shows CD3BiTE-mediated secretion of IFNγ from normal donor peripheral blood mononuclear cells (PBMCs) in the presence of MDA-MB-231 luc cells. -3Cells / well were seeded. ND#230341 (positive control) and PBMCs from 4 normal donors were used as effector cells. The effector / tumor cell ratio was 10 / 1. 140 μg / ml CD3BiTE was used. 72 hours after plate setup, supernatants were harvested for IFNγ assay.
[0033] Figure 5 is a pair of bar graphs. Figure 5A shows that a significant increase in cancer cell killing was demonstrated by LDH release assay in supernatants of effector:tumor cells (10:1) treated with 0 ng / ml+PBMC or 100 ng / ml+PBMC for 72 hours. Figure 5B shows that IFNγ secretion was significantly increased in three breast cancer cell lines treated with K3Bi (100 ng / ml) for 72 hours. Samples of untreated cells, peripheral blood mononuclear cells only, or BiTE only were used.
[0034] Figure 6 is a series of line graphs showing the efficacy of bispecific T cell-engaging antibodies (BiTEs) targeting HERV-K. NOD / SCID / IL-2Rγnull (NSG) mice were inoculated with MDA-MB-231 HERV-K positive cells on day zero and administered peripheral blood mononuclear cells or BiTEs on the days indicated. Tumor volumes were calculated throughout the assay by measuring tumor volume using calipers. DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
[0035] Usefulness of the invention This specification provides a method for producing a humanized anti-HERV-K antibody. The anti-tumor effect of hu6H5 has been demonstrated in vitro and in vivo.
[0036] The present invention provides a method for treating a patient suffering from cancer. In a twentieth embodiment, the present invention provides a method for treating cancer, comprising administering a therapeutic humanized anti-HERV-K antibody, or a CAR, BiTE, or a fusion thereof consisting of an antibody drug conjugate, optionally in combination with one or more immune checkpoint inhibitors. Each therapeutic agent targets the immune system individually. In a twenty-first embodiment, the method of the present invention inhibits metastasis. In a twenty-second embodiment, the method of the present invention reduces tumor size. In a twenty-third embodiment, the method of the present invention inhibits tumor cell proliferation. In a twenty-fourth embodiment, the method of the present invention detects cancer and cancer metastasis.
[0037] definition For convenience, the meanings of some terms and phrases used in the specification, examples, and the appended claims are listed below. Unless otherwise specified or implied from the context, these terms and phrases have the following meanings. These definitions are intended to help explain certain embodiments and are not intended to limit the claimed invention. Unless otherwise defined, all technical and scientific terms have the same meaning as commonly understood by those skilled in the art of molecular biology. If there is an obvious discrepancy between the meaning of a term in the art and the definition provided herein, the meaning provided herein shall prevail.
[0038] 5-Aza has its designated meaning in the biotechnology field as 5-azacytidine.
[0039] 6H5 has a biotechnology-recognized meaning as a murine anti-HERV-K monoclonal antibody developed in our laboratory.
[0040] "About" has its recognized meaning in the biotechnology arts and varies depending on the context in which the term is used. If there are uses of the term that are not clear to a person of ordinary skill in the biotechnology arts given the context in which it is used, "about" will mean up to plus or minus 10% of the value.
[0041] Antibody-drug conjugates (ADCs) are a biotechnology-recognized term for highly potent biological drugs constructed by attaching, using either permanent or labile linkers, small molecule anticancer or other therapeutic agents to antibodies that target specific antigens found only on target cells.
[0042] The B7 family has a recognized meaning in the biotechnology field as inhibitory ligands with undefined receptors. The B7 family includes B7-H3 and B7-H4, both of which are upregulated in tumor cells and tumor-infiltrating cells. The complete hB7-H3 and hB7-H4 sequences are available in GenBank accession numbers Q5ZPR3 and AAZ17406, respectively.
[0043] BiTE has its biotechnology art recognized meaning of bispecific T cell inducing antibody. BiTE refers to a recombinant bispecific protein that combines two scFvs from two antibodies; one targets a cell surface molecule (e.g., CD3ε) on a T cell and the other targets an antigen on the surface of a malignant cell. The two scFvs are linked by a short flexible linker. The term DNA-encoded BiTE (DBiTE) includes DNA plasmids encoding any BiTE that can be expressed in vivo.
[0044] Cancer antigen or tumor antigen has the meaning recognized in the biotechnology arts of (i) a tumor-specific antigen, (ii) a tumor-associated antigen, (iii) a cell expressing a tumor-specific antigen, (iv) a cell expressing a tumor-associated antigen, (v) a fetal antigen on a tumor, (vi) an autologous tumor cell, (vii) a tumor-specific membrane antigen, (viii) a tumor-associated membrane antigen, (ix) a growth factor receptor, (x) a growth factor ligand, or (xi) any other type of antigen or antigen-presenting cell or substance associated with cancer.
[0045] Combination therapy has its recognized meaning in the medical arts and includes the sequential administration of each agent or therapy of a regimen, thereby providing a beneficial effect from combining and substantially simultaneously administering these agents or therapies (e.g., in the form of a single capsule containing a fixed ratio of these active agents or in the form of multiple separate capsules for each agent). Combination therapy also includes combinations in which the individual elements may be administered at separate times and / or by different routes, but which act in combination to provide a beneficial effect due to the synergy or pharmacokinetic and pharmacodynamic effects of each agent of the combination therapy, or tumor treatment approach.
[0046] CTL has the biotechnology-recognized meaning of cytolytic or cytotoxic T cell.
[0047] Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) has its biotechnology-recognized meaning as a T-cell surface molecule that is a member of the immunoglobulin superfamily. The protein downregulates the immune system by binding to CD80 and CD86. The term CTLA-4 includes human CTLA-4 (hCTLA-4), variants, isoforms, species homologs of hCTLA-4, and analogs that share at least one epitope in common with hCTLA-4. The complete hCTLA-4 sequence is available in GenBank accession number P16410.
[0048] DCIS has the meaning recognized in the biotechnology field as ductal carcinoma in situ.
[0049] "Derived from a specified polypeptide or protein" has the biotechnology art recognized meaning of polypeptide origin. Preferably, a polypeptide or amino acid sequence derived from a particular sequence has an amino acid sequence essentially identical to that sequence or a portion thereof, the portion consisting of at least 10-20 amino acids, preferably at least 20-30 amino acids, more preferably at least 30-50 amino acids, or otherwise identifiable to one of ordinary skill in the molecular biology art as having that origin in the sequence. A polypeptide derived from another peptide may have one or more mutations relative to the starting polypeptide, e.g., one or more amino acid residues substituted with other amino acid residues, or may have one or more amino acid residues inserted or deleted. A polypeptide may include an amino acid sequence that is not naturally occurring. Such variants have less than 100% sequence identity or similarity to the starting molecule. In some embodiments, the peptide is encoded by a nucleotide sequence. The nucleotide sequences of the invention may be useful for several applications, including, for example, cloning, gene therapy, protein expression and purification, introduction of mutations, DNA vaccination of a host in need, generation of antibodies, e.g., for passive immunization, PCR, generation of primers and probes, and the like.
[0050] Effector cells have the biotechnology recognized meaning of immune cells that are involved in the effector phase of an immune response, as opposed to the cognitive and activation phases of the immune response. Exemplary immune cells include cells of myeloid or lymphoid origin, such as lymphocytes (B cells and T cells, such as cytolytic T cells (CTLs)), killer cells, natural killer cells, macrophages, monocytes, eosinophils, polymorphonuclear cells (e.g., neutrophils, granulocytes, mast cells, basophils), and the like. Some effector cells express specific Fc receptors (FcRs) and carry out specific immune functions.
[0051] Env has its biotechnology-recognized meaning of viral envelope protein. env has its biotechnology-recognized meaning of viral envelope RNA.
[0052] Epitope has the meaning recognized in the biotechnology arts as a protein determinant capable of specific binding to an antibody. Epitopes usually consist of surface groupings of molecules such as amino acids or sugar side chains, and usually have specific three-dimensional structural characteristics and specific charge characteristics. Conformational and nonconformational epitopes are distinguished by the fact that the binding to the former but not the latter is lost in the presence of denaturing solvents. Epitopes may include amino acid residues that are directly involved in binding (also called the immunodominant component of the epitope) and other amino acid residues that are not directly involved in binding (such as amino acid residues that are effectively blocked by a specific antigen-binding peptide). (The amino acid residues are within reach of the peptide that specifically binds to the antigen).
[0053] FACS has the meaning recognized in the biotechnology arts as fluorescence activated cell sorting.
[0054] Framework region has its biotechnology-recognized meaning as a subdivision of the variable region of an antibody (Fab), which consists of seven amino acid regions, four of which are framework regions and three of which are hypervariable regions.
[0055] HERV has its biotechnology-recognized meaning of human endogenous retrovirus. A human endogenous retrovirus (HERV) is a retrovirus that exists in the form of proviral DNA integrated into the genome of all normal cells and is transmitted by a Mendelian pattern of inheritance. HERV-X (where X is an English letter) has its biotechnology-recognized meaning of other HERV families.
[0056] HERV-K has a recognized meaning in the biotechnology field as the HERV-K family of endogenous retroviruses. HERV-K is expressed in many tumor types, including but not limited to melanoma, breast cancer (Wang-Johanning et al. (2003)), ovarian cancer (Wang-Johanning et al. (2007)), lymphoma, and teratocarcinoma. Infected cells, including those infected with HIV, also express HERV-K. This provides an attractive opportunity that one CAR design targeting HERV-K may be used to treat a variety of cancers and infectious diseases. It has the meaning recognized in the field of biotechnology as a humanized mouse.
[0057] HTM has the meaning recognized in the biotechnology arts as human tumor mouse.
[0058] hTAb has the biotechnology art recognized meaning of fully human tumor antibody.
[0059] Human endogenous retrovirus-K, HERV-K, HERV, human endogenous retrovirus, endogenous retrovirus, and ERV include any mutants, isoforms, and species homologs of an endogenous retrovirus that are naturally expressed by a cell or expressed on a cell transfected with an endogenous retroviral gene.
[0060] ICP has the meaning recognized in the biotechnology field as immune checkpoint.
[0061] IDC has its recognized meaning in the biotechnology field as invasive ductal carcinoma.
[0062] IHC has its recognized meaning in the biotechnology field: immunohistochemistry.
[0063] ILC has its recognized meaning in the biotechnology arts as invasive lobular carcinoma.
[0064] Immune cells are cells of hematopoietic origin that play a role in immune responses. Immune cells include lymphocytes (e.g., B cells and T cells), natural killer cells, and myeloid cells (e.g., monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes).
[0065] Immune checkpoint inhibitors have their biotechnology art recognized meaning of a molecule that fully or partially reduces, inhibits, interferes with, or modulates one or more checkpoint proteins. In some embodiments, the immune checkpoint inhibitor blocks the inhibitory signal associated with an immune checkpoint. In some embodiments, the immune checkpoint inhibitor is an antibody or fragment thereof that disrupts the inhibitory signaling associated with an immune checkpoint. In some embodiments, the immune checkpoint inhibitor is a small molecule that disrupts the inhibitory signaling. In some embodiments, the immune checkpoint inhibitor is an antibody, fragment thereof, or antibody mimic that prevents the interaction between checkpoint inhibitor proteins, e.g., an antibody or fragment thereof that prevents the interaction between PD-1 and PD-L1. In some embodiments, the immune checkpoint inhibitor is an antibody or fragment thereof that blocks the interaction between CTLA-4 and CD80 or CD86. In some embodiments, the immune checkpoint inhibitor is an antibody or fragment thereof that blocks the interaction between LAG3 and its ligand, or between TIM-3 and its ligand. The checkpoint inhibitor can also be a soluble form of the molecule (or a variant thereof) itself, e.g., a soluble PD-L1 or a PD-L1 fusion.
[0066] Immune checkpoints have their biotechnology recognized meaning of costimulatory and inhibitory signals that regulate the magnitude and quality of T cell receptor recognition of antigen. In some embodiments, the immune checkpoint is an inhibitory signal. In some embodiments, the inhibitory signal is the interaction between PD-1 and PD-L1. In some embodiments, the inhibitory signal is the interaction between CTLA-4 and CD80 or CD86 to displace CD28 binding. In some embodiments, the inhibitory signal is the interaction between a LAG3 molecule and an MHC class II molecule. In some embodiments, the inhibitory signal is the interaction between TIM3 and galectin 9.
[0067] In vivo has its meaning recognized in the biotechnology arts as a process that occurs in a living organism. The terms mammal or subject or patient include both humans and non-humans, including, but not limited to, humans, non-human primates, dogs, cats, rodents, cattle, horses, and pigs.
[0068] "Inhibit proliferation" (e.g., with reference to cells, such as tumor cells) has its biotechnology art-recognized meaning of a measurable decrease in proliferation of cells when contacted with a HERV-K specific therapeutic agent compared to the proliferation of the same cells not contacted with the HERV-K specific therapeutic agent, e.g., an inhibition of proliferation of a cell culture by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. Such a decrease in proliferation of cells can occur through a variety of mechanisms, e.g., apoptosis, exerted by anti-HERV-K agents individually or in combination.
[0069] ISD has its biotechnology-recognized meaning of immunosuppressive domain.
[0070] K-CAR or HERV-K envCAR has its biotechnology art-recognized meaning of a HERV-K envelope gene (surface or transmembrane) chimeric antigen receptor (CAR) gene construct. The term HERV-Kenv CAR-T cell or K-CAR-T cell has its biotechnology art-recognized meaning of a T cell transduced with a K-CAR or HERV-Kenv CAR lentivirus or Sleeping Beauty expression system.
[0071] KD has the meaning recognized in the biotechnology arts of knockdown (usually by shRNA).
[0072] KSU has its biotechnology-recognized meaning of HERV-K envelope surface fusion protein.
[0073] KTM has its biotechnology-recognized meaning of HERV-K Env transmembrane protein.
[0074] "Linked, fused, and fusion" are used synonymously. These terms have their recognized meaning in the biotechnology arts of joining two or more elements, components, or domains by any means, including chemical conjugation or recombinant methods. Methods of chemical conjugation (e.g., using heterobifunctional crosslinkers) are well known in the art.
[0075] Linker or linker domain has its biotechnology art recognized meaning as a sequence that connects two or more domains (e.g., a humanized antibody targeting HERV-K and an antibody targeting a T cell protein) in a linear sequence. Constructs suitable for the disclosed methods may use one or more linker domains, such as polypeptide linkers.
[0076] Lymphocyte activation gene 3 (LAG3) has its recognized meaning in the biotechnology arts as an inhibitory receptor associated with inhibition of lymphocyte activity by binding to MHC class II molecules. This receptor enhances the function of Treg cells and inhibits the function of CD8+ effector T cells. LAG3 includes human LAG3 (hLAG3), variants, isoforms, species homologs, and analogs of hLAG3 that share at least one common epitope. The complete hLAG3 sequence is available in GenBank accession number P18627.
[0077] Mammospheres have the biotechnology recognized meaning of mammary or breast cells cultured under non-adherent, non-differentiating conditions that form discrete clusters of cells.
[0078] MDA-MB-231pLVXC or 231-C refers to MDA-MB-231 cells transduced with pLVXC.
[0079] MDA-MB-231pLVXK or 231-K refers to MDA-MB-231 cells transduced with pLVXK.
[0080] Nucleic acid has the meaning recognized in the biotechnology arts of deoxyribonucleotides or ribonucleotides and their polymers in single-stranded or double-stranded form.Unless otherwise specifically limited, it includes nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides.Unless otherwise indicated, a particular nucleic acid sequence also implicitly includes its conservatively modified variants (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated.Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced with mixed bases and / or deoxyinosine residues. See Batzer et al., Nucleic Acid Res., 19, 5081 (1991); Ohtsuka et al., Biol. Chem., 260, 2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes, 8, 91-98 (1994). In the case of arginine and leucine, modifications of the base at the second position can also be conservative. The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.
[0081] PBMC has its biotechnology recognized meaning of peripheral blood mononuclear cells.
[0082] PDX has the biotechnology-recognized meaning of patient-derived xenograft, and are typically generated by transplanting human tumor cells or tumor tissue into immunocompromised mouse models of human cancer.
[0083] Percent identity refers to two or more sequences or subsequences with a certain percentage of identical nucleotides or amino acid residues when compared and aligned for maximum correspondence in the context of two or more nucleic acid or polypeptide sequences, as determined using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN, or other algorithms available to those skilled in the art) or by visual inspection. Depending on the application, the percent identity may be over a region of the sequences being compared, such as a functional domain, or over the entire length of the two sequences being compared. For sequence comparison, typically one sequence acts as a reference sequence to which a test sequence is compared. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, subsequence coordinates are designated, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence relative to the reference sequence based on the designated program parameters. Optimal alignment of sequences for comparison can be carried out, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math., 2, 482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol., 48, 443 (1970), the search for similarity method of Pearson & Lipman, Proc. Natl. Acad. Sci., USA, 85, 2444 (1988), computerized implementations of these algorithms (GAP, BESHERV-KIT, FASTA, and HERV-KASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI, USA), or by visual inspection. One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215, 403-410 (1990).Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information website.
[0084] "Pharmaceutically acceptable" generally means a compound, material, composition, and / or dosage form that is suitable, within the scope of sound medical judgment, for use in contact with the tissues, organs, and / or body fluids of humans and animals and is free from excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit / risk ratio.
[0085] pLVXC has its biotechnology art-recognized meaning as a control expression vector only.
[0086] pLVXK has its biotechnology-recognized meaning as a HERV-K expression vector.
[0087] Polypeptide linker has the biotechnology-recognized meaning of a peptide or polypeptide sequence (e.g., a synthetic peptide or polypeptide sequence) that connects two or more domains in the linear amino acid sequence of a polypeptide chain. Such a polypeptide linker can provide flexibility to the polypeptide molecule. The polypeptide linker can link (e.g., genetically fuse) one or more Fc domains and / or drugs.
[0088] Programmed death ligand-1 (PD-L1) is one of two cell surface glycoprotein ligands for PD-1 (the other being PD-L2) and downregulates T cell activation and cytokine secretion upon binding to PD-1. PD-L1 includes human PD-L1 (hPD-L1), hPD-L1 variants, isoforms, species homologs, and analogs that share at least one common epitope with hPD-L1. The complete hPD-L1 sequence is available in GenBank under accession number Q9NZQ7.
[0089] The programmed death-1 (PD-1) receptor has its recognized meaning in the biotechnology field as an immunoinhibitory receptor belonging to the CD28 family. PD-1 is expressed primarily on previously activated T cells in vivo and binds to two ligands, PD-L1 and PD-L2. PD-1 includes human PD-1 (hPD-1), variants, isoforms, species homologs of hPD-1, and analogs that share at least one common epitope with hPD-1. The complete hPD-1 sequence is available in GenBank under accession number AAC51773.
[0090] Recombinant host cell (or simply host cell) has its biotechnology art-recognized meaning of a cell into which an expression vector has been introduced. Such terms refer not only to the particular subject cell but also to the progeny of such a cell. Because minor modifications may occur in successive generations due to mutations or environmental influences, such progeny may not be identical to the parent cell, but are still included within the scope of host cells. Recombinant host cells include, for example, CHO cells, HEK293 cells, transfectomas such as NS / 0 cells, and lymphocytic cells.
[0091] scFv has its biotechnology-recognized meaning of single-chain variable domain.
[0092] SU has its biotechnology-recognized meaning of HERV-K surface fusion protein.
[0093] By sufficient amount or amount sufficient is meant an amount sufficient to produce a desired effect, for example an amount sufficient to reduce the size of a tumor.
[0094] Synergy or synergism, in reference to the effect produced by two or more individual components, has its meaning recognized in the art of biotechnology as the phenomenon whereby the overall effect produced by those components, when utilized in combination, is greater than the sum of the effects of the individual components acting alone.
[0095] T cell has the biotechnology art recognized meaning of CD4+ T cell or CD8+ T cell. The term T cell includes TH1 cells, TH2 cells, and TH17 cells.
[0096] T-cell membrane protein-3 (TIM3) is an inhibitory receptor involved in the inhibition of lymphocyte activity by inhibiting TH1 cell responses. Its ligand is galectin 9, which is upregulated in various types of cancer. TIM3 includes human TIM3 (hTIM3), variants of hTIM3, isoforms, species homologs, and analogs that share at least one common epitope. The complete hTIM3 sequence is available in GenBank accession number Q8TDQo.
[0097] A therapeutically effective amount is an amount effective for ameliorating symptoms of the disease. Prevention can be considered treatment, and thus a therapeutically effective amount can be a prophylactically effective amount.
[0098] TM has its biotechnology-recognized meaning of HERV-K transmembrane protein.
[0099] TNBC has a recognized meaning in the biotechnology field: triple-negative breast cancer.
[0100] A transgenic non-human animal has the biotechnology art recognized meaning of a non-human animal having a genome that includes one or more human heavy and / or light chain transgenes or transchromosomes (either integrated or not integrated into the animal's native genomic DNA) and is capable of expressing fully human antibodies. A transgenic mouse can have a human light chain transgene and either a human heavy chain transgene or a human heavy chain transchromosome, and the mouse produces human anti-HERV-K antibodies when immunized with HERV-K antigen and / or cells expressing HERV-K. The human heavy chain transgene can be integrated into the chromosomal DNA of the mouse, as in the case of a transgenic mouse (e.g., HuMAb mouse), or the human heavy chain transgene can be maintained extrachromosomally, as in the case of a transchromosomal KM mouse, as described in WO02 / 43478. Such transgenic and transchromosomic mice (collectively referred to herein as transgenic mice) can produce multiple isotypes of human mAbs to antigens (such as IgG, IgA, IgM, IgD, or IgE) through VDJ recombination and isotype switching. Transgenic non-human animals can also be used to produce antibodies to specific antigens by introducing genes encoding such specific antibodies, e.g., operably linking such genes to genes expressed in the milk of the animal.
[0101] Treatment refers to the administration of an effective amount of a therapeutically active compound of the present invention to reduce, ameliorate, arrest, or eradicate (cure) the symptoms or disease state.
[0102] Vector has its biotechnology art-recognized meaning of a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a plasmid, which has its biotechnology art-recognized meaning of a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, in which additional DNA segments can be ligated to a viral genome. Some vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (such as non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Some vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as recombinant expression vectors (or expression vectors). Expression vectors useful in recombinant DNA techniques are often in plasmids. As the plasmid is the most commonly used form of vector, the terms plasmid and vector are used interchangeably herein. However, the invention is intended to include other forms of expression vectors, such as viral vectors, including replication defective retroviruses, adenoviruses and adeno-associated viruses, which serve equivalent functions.
[0103] Unless otherwise defined, scientific and technical terms used in this application shall have the meanings commonly understood by one of ordinary skill in the biomedical arts. The present invention is not limited to the particular methodology, protocols, reagents, etc. described herein, as these may vary.
[0104] The disclosure described herein does not involve human cloning processes, methods for altering the germline genetic identity of humans, the use of human embryos for industrial or commercial purposes, or procedures that alter the genetic identity of animals and are likely to cause suffering without substantial medical benefit to humans or animals, and to animals born as a result of such processes.
[0105] Antibodies for Cancer Therapy The development of cancer therapeutic antibodies such as Herceptin® (trastuzumab), Avastin® (bevacizumab), and Erbitux® (cetuximab) has saved tens of thousands of lives worldwide. In particular, the treatment of HER2-positive metastatic breast or ovarian cancer with trastuzumab has dramatically changed patient outcomes. Antibody therapeutics offer distinct advantages compared to small molecule drugs: (i) a defined mechanism of action; (ii) greater specificity and fewer off-target effects; and (iii) a predictable safety and toxicity profile. As extensive studies with anti-Her2 and anti-EGFR monoclonal antibodies have demonstrated, of the thousands of antibodies identified based on their ability to bind molecular targets with high affinity, only a few antibodies exhibit the properties required for clinically effective cancer cell killing. The efficacy of therapeutic antibodies is primarily mediated by their ability to elicit potent tumor cytotoxicity through direct induction of apoptosis in target cells or through effector-mediated functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
[0106] The main methodologies for antibody isolation are: (i) in vitro screening from libraries from immunized animals or synthetic libraries using phage or microbial display43-45, and (ii) isolation of antibodies after B-cell immortalization or cloning46-48. These methodologies suffer from one or both of the following drawbacks, which severely limit the number of unique antibodies that can be isolated: (i) the need for extensive screening to isolate even a few high-affinity antibodies, and (ii) the immune response against these antibodies when injected into humans. Thus, regardless of the methodology used to screen / isolate therapeutic monoclonal antibodies (mAbs), the rate of translation from discovery to the clinic is inefficient and cumbersome.
[0107] One advancement that has facilitated the approval of therapeutic mAbs has been the generation of humanized antibodies by complementarity determining region (CDR) grafting technology, in which the CDR sequences of a non-human antibody are grafted onto human framework sequences, thus retaining target specificity.
[0108] Humanized antibodies and antibody-drug conjugate (ADC) pharmaceutical compositions Cancer cells that overexpress HERV-K can be good targets for the anti-HERV-K humanized antibody and antibody-drug conjugate of the present invention, since more antibodies can be bound per cell. Thus, in the twenty-fifth embodiment, the cancer patient treated with the anti-HERV-K humanized antibody or antibody-drug conjugate of the present invention is, for example, a breast cancer, ovarian cancer, pancreatic cancer, lung cancer, or colorectal cancer patient diagnosed with HERV-K overexpression in their tumor cells.
[0109] Once the anti-HERV-K humanized antibodies or antibody-drug conjugates have been purified, they may be formulated into pharmaceutical compositions using well-known pharmaceutical carriers or excipients.
[0110] Pharmaceutical compositions can be formulated using pharma- ceutically acceptable carriers or diluents, as well as any other known adjuvants and excipients, under conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed. (Mack Publishing Co., Easton, Pa., 1995).
[0111] Pharmaceutically acceptable carriers or diluents, as well as other known adjuvants and excipients, must be suitable for the humanized antibody or antibody-drug conjugate of the present invention and the selected mode of administration. The suitability of carriers and other components of the pharmaceutical composition is determined based on the absence of significant adverse effects on the desired biological properties of the selected compound or pharmaceutical composition of the present invention. For example, it is determined based on the insubstantial effect on antigen binding (relative inhibition rate of 10% or less, relative inhibition rate of 5% or less, etc.).
[0112] Pharmaceutical compositions of the invention may include diluents, fillers, salts, buffers, surfactants (e.g., non-ionic surfactants such as Tween-20 or Tween-80), stabilizers (e.g., sugars or non-protein amino acids), preservatives, tissue fixatives, solubilizing agents, or other materials suitable for inclusion in a pharmaceutical composition.
[0113] The actual dosage level of the humanized antibody or antibody-drug conjugate in the pharmaceutical composition of the present invention may vary to obtain an amount of the humanized antibody or antibody-drug conjugate effective to achieve the desired therapeutic response for a particular patient, composition, and method of administration without causing toxicity to the patient. The selected dosage level will depend on various pharmacokinetic factors, such as the activity of the particular composition of the present invention used, the route of administration, the time of administration, the excretion rate of the particular compound used, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular composition used, the age, sex, weight, condition, general health and previous medical history of the patient to be treated, and similar factors well known in the medical arts.
[0114] The pharmaceutical composition can be administered by any suitable route and mode. Suitable routes for administering the humanized antibody or antibody-drug conjugate of the present invention are well known in the art and can be selected by those skilled in the art of molecular biology.
[0115] In a twenty-sixth embodiment, the pharmaceutical compositions of the invention may be administered parenterally.
[0116] The phrases "parenterally administered and parenterally administered" refer to modes of administration other than enteral and topical administration, usually by injection, and include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, intradermal, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural and intrasternal injection and infusion.
[0117] In a twenty-seventh embodiment, the pharmaceutical composition is administered by intravenous or subcutaneous injection or infusion.
[0118] Pharmaceutically acceptable carriers include any suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, antioxidants and absorption delaying agents, and the like that are physiologically compatible with the humanized antibody or antibody-drug conjugate of the present invention.
[0119] Examples of suitable aqueous and non-aqueous carriers that may be used in the pharmaceutical compositions of the present invention include water, saline, phosphate buffered saline, ethanol, glucose, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, corn oil, peanut oil, cottonseed oil, and sesame oil, carboxymethylcellulose colloidal solutions, injectable organic esters such as gum tragacanth and ethyl oleate, and / or various buffers. Other carriers are well known in the pharmaceutical art.
[0120] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions, and sterile powders for preparing sterile injectable solutions or dispersions.The use of such media and agents for pharmaceutically active substances is well known in the art.Except where any conventional media or agent is incompatible with the anti-HERV-K humanized antibody or antibody-drug conjugate of the present invention, its use in the pharmaceutical composition of the present invention is contemplated.
[0121] Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in dispersions, and by the use of surfactants.
[0122] The pharmaceutical composition of the present invention may also contain a pharma- ceutically acceptable antioxidant. For example, (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.; (3) metal chelating agents, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.
[0123] The pharmaceutical compositions of the present invention may also include isotonic agents, such as sugars, polyalcohols such as mannitol, sorbitol, glycerol, or sodium chloride in the composition. The pharmaceutical composition of the present invention may also contain one or more adjuvants (such as preservatives, wetting agents, emulsifiers, dispersing agents, antiseptics, or buffers) for the selected route of administration, which may increase the shelf life or effectiveness of the drug. The anti-HERV-K humanized antibody or antibody-drug conjugate of the present invention may be prepared with a carrier that protects the compound from rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Such carriers may include biodegradable, biocompatible polymers such as gelatin, glyceryl monostearate, glyceryl distearate, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, alone or in combination with wax, or other materials well known in the art of molecular biology. Methods for preparing such formulations are generally well known to those skilled in the art of molecular biology. See, for example, Sustained and Controlled Release Drug Delivery Systems, Robinson, ed. (Marcel Dekker, Inc., New York, 1978).
[0124] In the twenty-eighth embodiment, the anti-HERV-K humanized antibody or antibody-drug conjugate of the present invention can be formulated to ensure proper distribution in vivo. Pharmaceutically acceptable carriers for parenteral administration include sterile aqueous solutions or dispersions, and sterile powders for preparing sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Except in the case where a conventional media or agent is incompatible with the active compound, its use in the pharmaceutical composition of the present invention is contemplated. Supplementary active compounds can also be incorporated into the composition.
[0125] Injectable pharmaceutical compositions must typically be sterile and stable under the conditions of manufacture and storage. The compositions may be formulated as solutions, microemulsions, liposomes, or other ordered structures suitable for high drug concentrations. The carrier may be an aqueous or non-aqueous solvent or dispersion medium, including, for example, water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity may be maintained, for example, by using a coating such as lecithin, by maintaining the particle size required for dispersion, and by using surfactants. In many cases, it will be preferable to include an isotonic agent in the composition, for example, sugars, glycerol, polyalcohols such as mannitol, sorbitol, or sodium chloride. Prolonged absorption of the injectable composition may be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin. Sterile injectable solutions can be prepared by incorporating anti-HERV-K humanized antibody or antibody-drug conjugates in the required amount, optionally with one or a combination of the ingredients listed above, into a suitable solvent, followed by sterilization microfiltration. In general, dispersions are prepared by incorporating anti-HERV-K humanized antibody or antibody-drug conjugates into a sterile vehicle containing a basic dispersion medium and other necessary ingredients (e.g., from those listed above). In the case of sterile powders for preparing sterile injectable solutions, examples of preparation methods include vacuum drying and freeze-drying (lyophilization), which produces a powder of the active ingredient and any additional desired ingredients from its solution that has previously been sterile-filtered.
[0126] Sterile injectable solution can be prepared by incorporating the required amount of anti-HERV-K humanized antibody or antibody drug conjugate into a suitable solvent with one or a combination of the components listed above as necessary, and then sterilizing by precision filtration. In general, dispersion is prepared by incorporating anti-HERV-K humanized antibody or antibody drug conjugate into a sterile vehicle that contains a basic dispersion medium and other necessary components listed above. In the case of sterile powder for preparing sterile injectable solution, examples of preparation methods include vacuum drying and freeze-drying (lyophilization), which produces a powder of anti-HERV-K humanized antibody or antibody drug conjugate and any additional desired components from its solution that has been previously sterilized and filtered.
[0127] The pharmaceutical composition of the present invention may contain one anti-HERV-K humanized antibody or antibody-drug conjugate of the present invention, or a combination of anti-HERV-K humanized antibodies or antibody-drug conjugates of the present invention.
[0128] The effective dose and dosing regimen of the anti-HERV-K humanized antibody or antibody-drug conjugate depends on the disease or condition being treated and can be determined by those skilled in the art of molecular biology. A typical, non-limiting range of a therapeutically effective amount of the compound of the present invention is about 0.1-100 mg / kg. A typical, non-limiting range of a therapeutically effective amount of the anti-HERV-K humanized antibody or antibody-drug conjugate of the present invention is about 0.02-30 mg / kg, particularly for antibodies 011, 098, 114 or 111 disclosed herein. Further guidance regarding therapeutically effective amounts is provided in Hendrikx et al., Fixed dosing of monoclonal antibodies in oncology. Oncologist, 22(10), 1212-1221 (October 2017) and Lu et al., Development of therapeutic antibodies to treat diseases. Journal of Biomedical Science, volume 27, Article number 1 (January 2, 2020).
[0129] A physician of ordinary skill in the medical arts can easily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician may begin the dosage of the anti-HERV-K humanized antibody or antibody-drug conjugate used in the pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. An appropriate daily dose of the composition of the present invention will be the amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective amount will generally depend on the factors described above. Administration may be intravenous, intramuscular, intraperitoneal, or subcutaneous, for example, proximal to the target site. If necessary, the effective daily dose of the pharmaceutical composition may be administered as two, three, four, five, six or more subdoses, optionally in unit dosage form, spaced apart throughout the day. Although it is possible to administer the anti-HERV-K humanized antibody or antibody-drug conjugate of the present invention alone, it is preferred to administer the anti-HERV-K humanized antibody or antibody-drug conjugate as a pharmaceutical composition, as described above.
[0130] In a twenty-ninth embodiment, the anti-HERV-K humanized antibody or antibody drug conjugate is administered at a dose of 10 to 1500 mg / m 2 , e.g., 30 to 1500 mg / m 2 , or for example from 50 to 1000 mg / m 2 , or for example from 10 to 500 mg / m 2 , or for example from 100 to 300 mg / m 2 Such administration can be repeated, for example, 1 to 8 times, 3 to 5 times, etc. Administration can be performed by continuous infusion over a period of 2 to 24 hours, for example, 2 to 12 hours.
[0131] In a 30th embodiment, the anti-HERV-K humanized antibody or antibody drug conjugate is administered at a dose of 30 to 1500 mg / m 2 , e.g., 50 to 1000 mg / m 2 or 100 to 300 mg / m 2The drug may be administered by infusion every 3 weeks at a dose of 0.01 to 0.025 mg / kg / day. Such administration may be repeated, for example, 1 to 8 times, for example, 3 to 5 times. Administration may be by continuous infusion over a period of 2 to 24 hours, for example, 2 to 12 hours.
[0132] In a thirty-first embodiment, the anti-HERV-K humanized antibody or antibody-drug conjugate may be administered by slow continuous infusion over an extended period of time, such as 24 hours or more, to reduce toxic side effects.
[0133] In a thirty-second embodiment, the anti-HERV-K humanized antibody or antibody drug conjugate may be administered in a weekly dose of 50 mg to 2000 mg up to 16 times. Administration may be performed over 2 to 24 hours by continuous infusion. Such a dosing regimen may be repeated one or more times, for example after 6 or 12 months. The dosage may be determined or adjusted by measuring the anti-HERV-K humanized antibody or antibody drug conjugate of the present invention in the blood at the time of administration, for example by taking a biological sample and using an anti-idiotypic antibody that targets the antigen-binding region of the anti-HERV-K humanized antibody or antibody drug conjugate of the present invention. Further guidance on dosage is provided by Hendrikx et al., Fixed dosing of monoclonal antibodies in oncology. Oncologist, 22(10), 1212-1221 (October 2017) and Lu et al., Development of therapeutic antibodies to treat diseases. Journal of Biomedical Science, volume 27, Article number 1 (January 2, 2020).
[0134] In a thirty-third embodiment, the anti-HERV-K humanized antibody or antibody drug conjugate may be administered as a maintenance therapy, for example once a week for six months or more.
[0135] In a thirty-fourth embodiment, the antibody drug conjugate may be administered by a dosing regimen comprising one infusion of an antibody drug conjugate of the invention followed by an infusion of an anti-HERV-K antibody of the invention (such as the antibody 6H5hum).
[0136] Bispecific T cell-inducing antibody (BiTE) In a thirty-fifth embodiment, provided herein is a method for treating HERV-K positive cancer in a subject having a HERV-K positive cancer and in need of treatment, comprising administering to the subject a therapeutically effective amount of a bispecific antibody comprising two antigen-binding regions, one of which has binding specificity for CD3 or CD8 and the other of which has binding specificity for HERV-K.
[0137] In a thirty-sixth embodiment, the invention relates to a bispecific antibody comprising in tandem a first single chain human variable region that binds HERV-K and a second single chain human variable region that binds the T cell activation ligands CD3 or CD8, the first and second single chain human variable regions are in amino to carboxy order, there is a linker sequence between each segment, and a spacer polypeptide links the first and second single chain variable regions.
[0138] In a thirty-seventh embodiment of the method, the administration is intravenous or intraperitoneal.
[0139] In a thirty-eighth embodiment of the method, the bispecific binding molecule does not bind to T cells during said administering step.
[0140] In a thirty-ninth embodiment, the method further comprises administering to the subject T cells. In a particular embodiment, the T cells bind to the same molecule as the bispecific binding molecule.
[0141] In a fortieth embodiment, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of a bispecific binding molecule, a pharma- ceutically acceptable carrier, and T cells. In a fortieth embodiment, the T cells bind to the bispecific binding molecule. In a fortieth embodiment, the binding of the T cells to the bispecific binding molecule is non-covalent. In a fortieth embodiment, the administration is in combination with T cell infusion to the subject for the treatment of HERV-K positive cancer. In a fortieth embodiment, the administration is after treating the patient with T cell infusion. In a fortieth embodiment, the T cells are autologous to the subject to whom they are administered. In a fortieth embodiment, the T cells are allogeneic to the subject to whom they are administered. In a fortieth embodiment, the T cells are human T cells.
[0142] In a forty-eighth embodiment, the subject is a human.
[0143] In a forty-ninth embodiment of the method, the bispecific binding molecule is in a pharmaceutical composition, which further comprises a pharma- ceutically acceptable carrier.
[0144] In a fiftieth embodiment of the bispecific binding molecule, the bispecific binding molecule does not bind to soluble or cell-bound Fc receptors. In some embodiments of the bispecific binding molecule, the heavy chain is mutated to destroy the N-linked glycosylation site. In a fifty-first embodiment of the bispecific binding molecule, the heavy chain has an amino acid substitution that replaces the N-linked glycosylation site asparagine with an amino acid that does not function as a glycosylation site. In a fifty-second embodiment of the bispecific binding molecule, the heavy chain is mutated to destroy the C1q binding site. In a fifty-third embodiment, the bispecific binding molecule does not activate complement.
[0145] In a fifty-fourth embodiment of the bispecific binding molecule, the HERV-K positive cancer is breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, melanoma, colorectal cancer, small cell lung cancer, non-small cell lung cancer, or other tumor tissue expressing HERV-K. In a fifty-fifth embodiment, the HERV-K positive cancer is a primary tumor or a metastatic tumor, e.g., a metastasis to the brain, bone, or lung.
[0146] DNA-encoded bi-specific T Cell Engagers (DBiTE) DNA-encoded bispecific T cell-inducing antibody (DBiTE) Specific antibody therapy, including mAbs and bispecific T cell-inducing antibodies (BiTEs), is an important tool for cancer immunotherapy. BiTEs are a type of artificial bispecific monoclonal antibody that has the potential to change the landscape of cancer immunotherapy. BiTEs direct the host immune system, more specifically the cytotoxic activity of T cells, against cancer cells. BiTEs have two binding domains. One domain binds to the target tumor (such as HERV-K expressing cells), and the other domain engages the immune system by directly binding to a molecule on T cells. This dual binding activity triggers the activation of T cells directly at the tumor, triggering their killing function and tumor destruction. DBiTEs share many of the advantages of bispecific monoclonal antibodies. Both contain engineered DNA sequences that code for two antibody fragments. The patient's own cells become the factory to manufacture functional BiTES encoded by the provided DBiTE sequence. BiTE delivery and combinations of DBiTEs can be administered at once as a multi-pronged approach to treat resistant cancers. Synthetic DNA design of BiTE-like molecules involves encoding them into engineered and optimized synthetic plasmid DNA cassettes. DBiTEs are then injected locally into muscle, allowing muscle cells to convert the genetic instructions into proteins that can then be delivered to the bloodstream directly in vivo to seek out and destroy tumors. See Perales-Puchalt et al., JCI Insight, 4(8), e126086 (April 18, 2019). In preclinical studies, DBiTEs have demonstrated a unique profile compared to conventional BiTEs and have overcome some of the technical challenges associated with their manufacture. For more information, see also PCT patent publications WO2016 / 054153 (Wistar Institute of Anatomy and Biology) and WO2018 / 041827 (Psioxus Therapeutics Limited).
[0147] HERV-K CAR-T therapy Many formulations of CARs specific for target antigens have been developed. See, for example, International Pat. Publ. WO 2014 / 186469 (Board of Regents, the University of Texas System). Provided herein are methods for generating chimeric antigen receptor (CAR) modified T cells with long-lived in vivo potential, for example, to treat leukemia patients exhibiting minimal residual disease (MRD). Overall, the method describes a method for fusing soluble molecules, such as cytokines, to the cell surface to enhance therapeutic potential. The core of the method relies on co-modification of CAR T cells with a human cytokine mutein of interleukin 15 (IL-15), hereafter referred to as mIL15. The mIL15 fusion protein contains the codon-optimized cDNA sequence of IL-15 fused to the full-length IL15 receptor alpha via a flexible serine-glycine linker. This IL-15 mutein was designed to: (i) restrict mIL15 expression to the surface of CAR+ T cells, limiting cytokine spread to non-target in vivo environments and potentially improving their safety profile, since administration of exogenous soluble cytokines causes toxicity; and (ii) present IL-15 in the context of IL-15Ra to mimic physiologically relevant and qualitative signaling, as well as stabilization and recycling of the IL15 / IL15Ra complex for increased cytokine half-life. T cells expressing mIL15 are capable of continued supportive cytokine signaling, which is important for T cell survival after infusion. mIL15+CAR+ T cells, generated by genetic modification of the non-viral Sleeping Beauty System followed by ex vivo expansion in a clinically applicable platform, yielded a T cell infusion product with enhanced persistence after infusion in mouse models with high, low, or no tumor burden. mIL15 CAR+ T cells also demonstrated improved antitumor efficacy in both high and low tumor burden models. The hu6H5 scFv was used to generate K-CARs with lentiviral vectors.
[0148] Combination therapy The therapeutic method herein can be used without modification, since it relies on the binding of an antibody or fragment to a surface antigen of a HERV-K+ cancer cell in situ and stimulating an immune attack on the HERV-K+ cancer cell. The method can be carried out using an antibody or binding fragment to which a cytotoxic agent is attached. When the cytotoxic antibody or antibody binding fragment binds to a tumor cell, the cell's proliferation is inhibited or the cell is killed.
[0149] Antibodies specific for the HERV-K env protein can be used in conjunction with other expressed HERV antigens, which may be useful for immunotherapy or antibody therapy of diseases in which several different HERVs are expressed, for example, HERV-E in prostate cancer, ERV3, HERV-E, and HERV-K in ovarian cancer, and ERV3, HERV-H, and HERV-W in other cancers.
[0150] Cytokines within the common gamma chain receptor family (γC) are important costimulatory molecules for T cells that are crucial for lymphoid function, survival, and proliferation. IL-15 possesses several desirable attributes for adoptive therapy. It is a homeostatic cytokine that supports the survival of long-lived memory cytotoxic T cells, promotes eradication of established tumors by relieving functional suppression of tumor-resident cells, and inhibits activation-induced cell death (AICD). IL-15 is tissue-restricted and is observed at serum or systemic levels only under pathological conditions. Unlike other γC cytokines that are secreted into the surrounding environment, IL-15 is transpresented to T cells by producing cells in association with the IL-15 receptor alpha (IL-15Ra). This unique mechanism of delivery of the cytokine to T cells and other responding cells (i) is highly targeted and localized, (ii) increases the stability and half-life of IL-15, and (iii) generates signaling that is qualitatively distinct from that achieved by soluble IL-15.
[0151] Pharmaceutical Compositions The present specification is also directed to pharmaceutical compositions comprising a therapeutic agent that specifically binds to a HERV-K env protein, together with a pharma- ceutically acceptable carrier, excipient, or diluent. Such pharmaceutical compositions may be administered in any suitable manner, including parenterally, topically, orally, or topically (such as by aerosol or transdermal), or any combination thereof. Suitable regimens also include an initial administration by intravenous bolus injection, followed by repeated administrations at one or more intervals.
[0152] Pharmaceutical compositions of the compounds of the present disclosure are prepared for storage in lyophilized formulations or in aqueous solutions by mixing peptide ligand-containing compounds having the desired purity, as appropriate, with pharma- ceutically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences 18th ed., 1990). Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed.
[0153] The compositions herein may also contain multiple active compounds for the particular condition being treated, preferably compounds with complementary activities that do not harm each other. Or, the compositions may further contain cytotoxic agents, cytokines, growth inhibitors, or cardioprotectants. Suitably, such molecules are present in combination in amounts effective for the purpose. The present invention is further described in the following examples, which are not intended to limit the content or scope of the invention in any way. Example 1
[0154] Humanized antibodies produced commercially and in the inventor's laboratory The inventors have synthesized and purified humanized antibodies targeting the HERV-K tumor antigen. The HERV-K envelope surface gene tumor antigen (KSU) was derived from cancer cells of human patients, rather than from sequences in GenBank, which are HERV-K gene sequences from normal humans. The inventors have shown that these HERV-K sequences from cancer patients contain mutations that distinguish them from normal HERV-K sequences. The inventors' humanized antibodies are specific for HERV-K targets found in human cancer cells. This specificity distinguishes HERV-K targets present in human cancer cells from HERV-K targets present in tissues of normal individuals or patients with non-cancer diseases. This specificity also distinguishes our humanized antibodies against the HERV-K tumor antigen from other antibodies against the HERV-K tumor antigen.
[0155] This human antibody targeted the full-length surface protein of the HERV-K envelope gene, rather than a peptide or a small fragment of the gene, which is expressed only in cancer cells from cancer patients.
[0156] The scFv sequence from a mouse antibody against a HERV-K envelope surface fusion protein was submitted to a contract research organization (CRO) for the generation of a humanized antibody. The first CRO was unable to generate the light chain of our humanized antibody targeting HERV-K, indicating that the generation of a HER-K antagonist humanized antibody containing heavy and light chains is difficult to predict.
[0157] A second contract research organization produced a chimeric antibody that failed to bind to the HERV-K envelope surface fusion protein by ELISA, SPR, or Western blot assays, although binding of the chimeric antibody to our non-humanized mouse antibody was readily detected using ELISA or Western blot assays. This result also demonstrates that generating active HER-K antagonist humanized antibodies containing heavy and light chains is difficult to predict.
[0158] Next, we generated three humanized antibodies. Only one of the three humanized antibodies (HUM1, expressed in bacterial cells) bound to the HERV-K antigen. The expressed HUM2 or HUM3 proteins did not bind well to recombinant SU protein, especially not to SU protein produced from breast cancer cells (MDA-MB-231).
[0159] We then generated an additional humanized antibody, hu6H5. Hu6H5 was expressed in mammalian cells and its antitumor effect was determined. Both HUM1 and hu6H5 antibodies bound to the full-length KSU antigen.
[0160] The differences between HUM1, HUM2, and HUM3 are shown in Table 1 below for VH and Table 2 below for VL. HUM1, HUM2, and HUM3 were all produced from the same bacterial expression vector. All have the same CDRs for VH and VL. Hu6H5 was generated from a mammalian vector based on the HUM1 sequence. HUM1, HUM2, and HUM3 all bound to recombinant KSU protein. Only HUM1 bound to protein isolated from cancer cells.
[0161] This example also demonstrates that the medically useful functional properties of antibodies that bind to proteins isolated from cancer cells are not properties that arise from the structure of the VH and VL CDRs. Example 2
[0162] Comparison of hu6H5 sequences with sequences of other humanized anti-HERV-K antibodies and other antibodies targeting tumor antigens An anti-HERV-K antibody targeting amyotrophic lateral sclerosis (ALS), designated GN-mAb-Env_K01, binds to a HERV-K envelope linear peptide with the core sequence SLDKHKHKKLQSFYP. See US Pat. No. 10,723,787.
[0163] The hu6H5 antibody binds to the longer, full-length HERV-K envelope SU domain and not to linear peptides.
[0164] In contrast to GN-mAb-Env_K01, our humanized antibody was specific for the HERV-K ENV protein from cancer cell targets. The hu6H5 sequence shows little sequence similarity with the GN-mAb-Env_K01 humanized antibody; the identity is 60% in VH and 55% in VL.
[0165] BLAST searches showed that other antibodies targeting cancer-associated antigens shared minimal homology with hu6H5 (6-15 peptide). These included 82% identity with the VH of an anti-ErbB2 antibody (based on the crystal structure of anti-ErbB2 Fab2C4) that targets HER2-positive breast cancer, and 88% identity with the VL of anti-DREG-55 (anti-DREG-55 (L-selectin) immunoglobulin light chain variable region). Anti-DREG-55 targets L-selectin, which mediates adaptive and innate immunity in cancer.
[0166] The present inventors also identified human germline sequences near the boundaries of the CDRs in the humanized anti-HERV-K antibodies, including VRQAPGKGLEW (SEQ ID NO: 4) and LQMNSLRAEDTAVYYC (SEQ ID NO: 47). Example 3
[0167] Binding affinity and antibody internalization of anti-HERV-K humanized antibodies to HERV-K SU protein We determined by ELISA assay that the affinity of the HUM1 humanized antibody to HERV-K envelope surface fusion protein is as effective as that of its m6H5 at antibody concentrations above 0.00625 μg / ml and more effective than that of most of our other mouse monoclonal antibodies. See Figure 2. Our chimeric humanized anti-HERV-K antibody was shown by immunoblotting that its m6H5 mAb binds to two HERV-K Env surface proteins, ERVK6 and HERV-K envelope surface fusion protein.
[0168] To determine the internalization of humanized and mouse antibodies, cells were incubated with HUM1 or m6H5 at different time intervals (0, 5, 30, and 45 min) at 37°C and cells were fixed at each time point. Half of the cells were permeabilized and half were not. Anti-human IgG 488 or anti-mouse IgG 488 was used to detect the percentage of antibody-bound HERV-K env protein that remained on the cell surface in cells that were not permeabilized. A decrease in surface expression of HERV-K positive cells was observed. The internalization rate was measured in cells that were permeabilized. The formula for the percentage of internalization at each time point was 100-(% of label at time 0).
[0169] Results demonstrated increased expression of internalized HERV-K positive cells in cells treated with either HUM1 or murine 6H5 mAb, but HUM1 was cleared from the cell surface more rapidly than 6H5, indicating that uptake of our humanized antibody was more rapid than its murine counterpart. This rapid uptake supports the unique ability of HUM1 to deliver its payload more quickly than m6H5. Example 4
[0170] Cancer cell killing and apoptosis Transduction of HERV-K into 231K cells resulted in increased HERV-K expression in these cells. Flow cytometry results revealed that humanized (HUM1) and mouse (6H5) anti-HERV-K antibodies bound to MDA-MB-231 cells and that our therapeutic mAbs induced apoptosis more strongly in cells expressing high levels of HERV-K. We then evaluated the induction patterns of early and late apoptosis in BXPC 3 pancreatic cancer cells treated with hu6H5 and m6H5. The induction patterns were similar for both humanized and mouse mAbs. However, hu6H5 treatment resulted in an increase in both early and late apoptosis compared to m6H5 treatment, indicating the superiority of humanized mAb treatment over mouse mAb treatment. Data from these studies indicate that the presence of increased levels of HERV-K antigen in or on breast cancer cells allows our humanized anti-HERV-K antibodies to more effectively target and kill these cells by inducing both early and late apoptosis. Example 5
[0171] RNA expression patterns of breast cancer cell signaling pathways in response to the presence or absence of HERV-K protein overexpression The effect of HERV-K overexpression on the RNA expression of cell signaling pathway genes in MDA-MB-231 breast cancer cells (231K) was assessed by RNA sequencing (RNA-Seq) and compared with expression in non-transduced 231C cells. We demonstrated that the PI3K-Akt and TNF signaling pathways were strongly upregulated (>5-fold increase) in cells in which HERV-K expression was induced. Furthermore, MAPK, mTOR, NF-κB, Ras and the Ras-related protein Rap-1 showed a >3-fold increase in 231K cells compared to 231C cells. Treatment groups of immunodeficient mice (KC) were inoculated with 231K cells and compared with control groups of immunodeficient mice (C) inoculated with 231C cells. This in vivo group largely mirrored the results of the in vitro assay, showing a high upregulation of PI3K-Akt, TNF, MAPK, mTOR, and NF-κB, and a more moderate upregulation of Ras and Rap-1, in tumors from mice in the KC group. Example 6
[0172] Patterns of breast cancer cell signaling pathway protein expression in response to humanized and murine mAb treatment with or without HERV-K protein overexpression HERV-K was introduced into MDA-MB-231 human breast cancer cells by a retroviral vector as described in Example 4. The primary and secondary antibodies and their dilutions used for flow cytometry analysis of HERV-K and signal transduction pathway expression were: m6H5: 1:200; anti-mouse: 1:1,000 Ras: 1:200; anti-rat: 1:1,000 p-ERK: 1:200; anti-mouse; 1:1,000 SIRT-1: 1:200; Anti-rabbit: 1:1,000 CIDEA: 1:200; Anti-mouse: 1:1,000 p-Rb: 1:200; anti-rabbit; 1:1,000 PE-labeled caspase 3: 1:200 Primary antibody incubation: 1 hour at 4°C Secondary antibody incubation: 30 min at 4°C
[0173] We observed a decrease in the expression of HERV-K, Ras, p-ERK, and SIRT-1 in 231K cells treated with hu6H5, and the inhibitory effect of hu6H5 was much greater than that of murine m6H5 on these pathways. The positive effect of SIRT-1 expression on p53-mediated apoptosis and the negative regulation of p53-induced cellular senescence have been demonstrated, indicating that inhibition of SIRT1 activity increases p53 acetylation and transactivation, thereby enhancing apoptosis and inhibiting cell growth and proliferation. The observed expression changes for SIRT-1 after HERV-K antibody therapy have not been reported before. Therefore, inhibition of hu6H5-induced SIRT-1 expression is beneficial for cancer therapy and is in line with our previous findings that reduction of HERV-K expression has a significant impact on the p53 signaling pathway. Similarly, 231K cells treated with hu6H5 showed a greater increase in expression of proapoptotic caspase 3 and the tumor suppressor gene Rb than 231C cells, further supporting the efficacy of our humanized antibody in stimulating pathways that promote tumor cell death. Example 7
[0174] Determination of the percentage of CD3 or CD8 BiTE recombinant proteins using anti-GST mAb and BiTEs that bind to target cells The percentage of peripheral blood mononuclear cells containing anti-HERV-K scFv linked to either anti-CD3 or anti-CD8 antibodies was determined by flow cytometry using an anti-GST antibody tag. The percentage of CD3 BiTE ranged from 54.1% to 58.5%.
[0175] The percentage of CD8 BiTE ranged from 48.8% to 55.2%. Binding of CD3BiTE / CD8BiTE to their respective targets was assessed by ELISA. Wells were coated with CD3 epsilon or CD8 protein (1 μg / ml) and then increasing concentrations of BiTE were added. Mouse anti-GST was added followed by goat anti-mouse IgG-HRP (or isotype) and then ABTS was added for color development. ELISA results demonstrate that CD3BiTE binds to CD3 epsilon, but CD3BiTE also cross-reacts with CD8 protein. CD8BiTE bound to CD8 protein but did not cross-react with CD3 epsilon. Example 8
[0176] Effect of BiTE treatment on cancer cell killing Cell killing by both BiTEs was potent. Both CD3 and CD8 BiTE treatment increased cell killing of human breast (MDA-MB-231, MCF7), pancreatic (BxPC3), and mouse ovarian (ID8) cancer cells in vitro. Notably, in the LDH assay, mean fluorescence intensity increased from 125 to nearly 3,500 when MDA-MB-231 cells were treated with either CD3 or CD8 BiTEs, and a similar, but less dramatic, increase in cell killing was observed in other cell lines. Direct microscopic observation of MDA-MB-231 cells treated with HERV-K CD3 BiTEs at concentrations of 0, 0.03, 0.3, 30, and 300 ng / ml of BiTE also revealed a dose-response and time effect of CD3 BiTE targeting HERV-K on killing of MDA-MB-231 cells. Higher BiTE concentrations and longer treatment times increased cell death. However, when cancer cells were treated with BiTEs alone, without the addition of peripheral blood mononuclear cells or T cells, cell death did not increase. The large increase in cell killing in the presence of T cells supports the in vitro efficacy of HERV-K-targeting BiTEs. Example 9
[0177] Design of humanized single-chain variable domain (scFv) antibodies Antibody Numbering System and CDR Definitions: The antibody numbering server is part of the KabatMan database and follows the enhanced Chothia system. Working Example This humanized antibody was used to number all of the antibody sequences. Working Example In this study, we combined the enhanced Chothia numbering with the Contact CDR definition of the antibody sequence to place the CDRs of the antibody light and heavy chains at the following positions: H-CDR1 30-35, H-CDR2 47-58 H-CDR3 93-101, L-CDR1 30-36, L-CDR2 46-55, L-CDR3 89-96.
[0178] Human template selection To generate the humanized scFv gene, the six complementarity determining regions (CDRs) of mouse VH and VL were grafted onto the human framework (FR) that showed the highest amino acid sequence identity for antibody humanization. FWJ Used as the human FR selected for antibody clones. Human and mouse FWJ Human immunoglobulin germline sequences showing the highest amino acid sequence similarity in the FRs between VH and VL were independently identified using the V-quest server (http: / / www.imgt.org / IMGT_vquest) and the Ig-BLAST server (http: / / www.ncbi.nlm.nih.gov / igblast). The heavy chain VHIII and light chain KI selected were based on the conserved germline. The consensus human FRs were: FWJ The mouse VH and VL FRs were designed between the germline genes selected for grafting of CDR residues. The amino acid sequences of the FRs of mouse VH and VL that differed from the consensus human FRs were replaced with human residues while retaining mouse residues at positions known as Vernier zone and chain packing residues. Table 1 VHs from HUM1, HUM2, and MuVH VH CDRs SCKASGYSFTGYYMHWV---IGRVNPNSGGTSYNQKFKD---CARSKGNYFYAMDY Hum2_VH EVQLVESGGGLVQPGGSLKVSCKASGYSFTGYYMHWVRQASGKGLEWIGRVNPNSGGTSY HUM1_VH EVQLVESGGGLVQPGGSLRLSCKASGYSFTGYYMHWVRQAPGKGLEWIGRVNPNSGGTSY FWJ_MUVH QVKLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSHGKSLEWIGRVNPNSGGTSY :*:* :** .**:**.*:::*****************:*: **.**************** Hum2_VH NQKFKDRFTISRDKSISTLYLQMSSLRSEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSS HUM1_VH NQKFKDRATLSVDNSKNTAYLQMNSLRAEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSS FWJ_MUVH NQKFKDKAILTVDKSSSTAYMELRSLTSEDSAVYYCARSKGNYFYAMDYWGQGTTVTVSS ******::: *:* .* *::: ** :**:*********************** ***** Hum2_VH (SEQ ID NO: 7) HUM1_VH (SEQ ID NO: 6) FWJ_MUVH (Sequence number: 8) A "*" indicates that the residue or nucleotide in that row is identical in all sequences in the alignment. The ":" indicates that a conservative substitution is observed. The "." indicates that semi-conservative substitutions are observed, i.e., amino acids with similar shapes. Table 2 VL comparison from HUM2, HUM3, and MuVL VL CDRs CRASESVDSHGTSFMH---RASNLE---QQSNEDPPT HUM2_VL DIQMTQSPSSLSASVGDRVTITCRASESVDSHGTSFMHWYQQKPGKAPKFLIYRASNLES HUM3_VL DIQMTQSPSSLSASVGDRVTISCRASESVDSHGTSFMHWYQQKPGKSPKFLIYRASNLES FWJ_MUVL DIELTQSPASLAVSLGQRATISCRASESVDSHGTSFMHWYQQKPGQPPKFLIYRASNLES **::****:**:.*:*:*.**:***********************:.************* HUM2_VL GIPSRFSGSGSGTDFTLTISSVQPEDFAVYYCQQSNEDPPTFGGGTKVEIK HUM3_VL GIPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSNEDPPTFGGGTKVEIK FWJ_MUVL GIPARFSGSGSRTDFTLTINPVETDDVAIYYCQQSNEDPPTFGGGTKLEIK ***:***.*** *******..::.:*.*:******************:*** HUM2_VL (SEQ ID NO: 9) HUM3_VL (SEQ ID NO: 10) FWJ_MUVL (Sequence number: 11) Although the CDRs in both mouse and human are identical, as highlighted by the yellow background in Table 2, significant differences in the remainder of the VL sequence may partly explain the inability of HUM2 and HUM3 to bind human cancer cell HERV-K envelope protein.
[0179] Gene clones of variable heavy and light chains of FWJ_1 and FWJ_2 antibodies were amplified and synthesized. The genes encoding scFv are VH-linker-VL with a standard 20 amino acid linker ((Gly4Ser)3GGGAR (SEQ ID NO: 14). The amplified genes were digested with BssHII and NheI restriction enzymes and inserted with a C-terminal 6x histidine tag into a pET-based vector (PAB-myc) containing the pelB promoter (Novagen, Madison, WI, USA) controlling periplasmic protein expression for purification by metal affinity chromatography, and transformed into DH5α bacterial strain. The transformed clones were amplified overnight in L medium containing ampicillin broth. Plasmid DNA was prepared and sent for DNA sequencing. The correct sequence of the scFv plasmid was transformed into T7 Shuffle bacterial strain, and the transformed bacteria were used for soluble protein production in the periplasmic compartment.
[0180] FWJ_1 and FWJ_2_scFv_ gene and translated protein sequences: The sequence listing represents the heavy and light chains and linker arms of FWJ_1 and FWJ_2_scFv. In engineering the FWJ_1 and FWJ_2_scFv genes, two epitope tags were engineered at the carboxyl terminus: (1) a six His tag to facilitate purification of the encoded scFv by nickel affinity chromatography; (2) a myc tag to facilitate rapid immunochemical recognition of the expressed scFv.
[0181] Induction of ScFv proteins in bacterial hosts:FWJ_1 and FWJ_2 scFv clones were transformed into T7 Shuffle bacterial strain. T7 Shuffle cells were grown in 1.4 L of 2xYT medium supplemented with ampicillin at 37°C to logarithmic phage (OD600=0.5), induced with 0.3 mM IPTG, and grown for an additional 16 hours at 30°C. After induction, bacteria were harvested by centrifugation at 8000g for 15 minutes at 4°C, and the pellet was stored at -20°C for at least 2 hours. The frozen pellet was briefly thawed and suspended in 40 ml of lysis buffer (1 mg / ml lysozyme and EDTA-free protease inhibitor cocktail in phosphate-buffered saline (Thermo Scientific, Waltham, MA, USA). The lysis mixture was incubated on ice for 1 h, then 10 mM MgCl2 and 1 μg / ml DNaseI were added and the mixture was incubated at 25 °C for 20 min. The final lysis mixture was centrifuged at 12000g for 20 min and the supernatant was collected. This supernatant was referred to as the periplasmic extract used for nickel column affinity chromatography.
[0182] Western blot analysis using FWJ_1 and FWJ_2_scFv proteins: Lysate Ag and HERV-K envelope surface fusion proteins were used as antigen targets in dot blot analysis. 2-5 μg of Ag protein as protein under non-reducing conditions and 1 μg of purified protein as negative control were loaded onto nitrocellulose membrane. The membrane was blocked using 3% skim milk in phosphate buffered saline for 3 h at room temperature. Then, the membrane was incubated with periplasmic extracts of FWJ_1 scFv protein and FWJ_2 scFv protein at 4 °C overnight. The membrane was washed three times with sodium phosphate buffered saline containing 0.05% Tween 20 buffer (PBST). The washed membrane was incubated with anti-c-Myc mouse IgG for 1 h at room temperature to recognize the c-Myc tag on the scFv and identify the location of the antigen to which the scFv binds. After washing with PBST, the membrane was incubated with goat anti-mouse IgG (H+L) HRP conjugate diluted in phosphate-buffered saline (1:3000 v / v) for 1 h at room temperature, and specific immunoreactive bands were visualized using a mixture of TMB substrates.
[0183] We identified anti-HERV-K mAb 6H5 heavy chain CDRs (H-CDR1 30-35, H-CDR2 47-58, H-CDR3 93-101) and light chain CDRs (L-CDR1 30-36, L-CDR2 46-55, and L-CDR3 89-96) and grafted them into selected human frameworks (FRs) that showed the highest amino acid sequence identity to optimize the humanization of the antibody. Human immunoglobulin germline sequences that showed the highest amino acid sequence similarity in FRs between human and mouse VH and VL were identified separately from V-quest (http: / / www.imgt.org / IMGT_vquest) and Ig-BLAST (http: / / www.ncbi.nlm.nih.gov / igblast) servers. Amino acid sequences of mouse VH and VL FRs that differed from the consensus human FRs were replaced with human residues, while mouse residues at positions known as Vernier zone residues and chain packing residues were retained. VH and VL chain clones of candidate humanized antibody genes were amplified and synthesized. Genes encoding scFvs, including VH-linker-VL with the standard 20 amino acid linker (Gly4Ser)3GGGAR (SEQ ID NO: 14), were inserted into a pET-based vector (PAB-myc) containing the pelB promoter controlling the expression of periplasmic proteins, along with a C-terminal 6x histidine tag for purification by metal affinity chromatography and a myc tag to facilitate rapid immunochemical recognition of the expressed scFvs (Novagen, Madison, WI, USA). The correct sequence of the scFv plasmid was used for the production of soluble proteins in the periplasmic compartment. Two hu6H5 clones (FWJ1 and FWJ2) were selected and their binding affinity to the antigen was determined. Both clones bound antigen generated from recombinant HERV-K Env surface fusion protein (KSU) and to lysates from MDA-MB-231 breast cancer cells.
[0184] HuVH or HuVL with human IgG1 were cloned into pcDNA 3.4 vector to generate VH-CH (human IgG1) or VL-CL (human kappa). For mammalian expression, the plasmids were transiently transfected into Expi293 cells. The ratio of H chain plasmid to L chain plasmid is 2:3. Expression was determined using Western blot, and the predicted molecular weight of 49 / 23 kDa (heavy chain / light chain) was detected under reducing conditions. Western blot was used to detect the VH chain and VL chain of the humanized anti-HERV-K antibody in SDS-PAGE gel under reducing conditions. A molecular weight of 49 KDa for the VH chain and 23 KDa for the VL chain were detected.
[0185] Size-exclusion chromatography (SEC) separation by size and / or molecular weight was further used to determine protein expression. Size-exclusion chromatography (SEC) separation by size and / or molecular weight was further used to measure protein expression. Only two peaks were detected, with the concentration of peak 2 being >99% of the combined size of peaks 1 and 2. Humanized 6H5 antibody (purity >95%) with endotoxin levels <1EU / mg was used to determine antitumor efficacy in vitro and in vivo.
[0186] An ELISA assay was used to compare the antigen-binding sensitivity and specificity of hu6H5 and m6H5, see Figure 2. No significant differences were detected between these two parameters.
[0187] Apoptosis assays were used to compare the efficacy of hu6H5 and m6H5 in killing cancer cells. MDA-MB-231 breast cancer cells were treated with the respective antibodies (1 or 10 μg per ml) for 4 and 24 h. Apoptosis assays were used to measure the cytotoxicity of murine and humanized anti-HERV-K antibodies against cancer cells. Cancer cells containing MDA-MB-231-pLVXK (231K) (a breast cancer cell line transduced with a pLVX vector expressing the HERV-K env protein) or MDA-MB-231-pLVXC (231C) (the same breast cancer cell line, transduced using a pLVX empty vector) were treated with m6H5 or hu6H5 (1 or 10 μg per ml) for 4 or 16 h. The percentage of apoptotic cells was determined using Annexin V and 7AAD.
[0188] Cells treated without antibody or with mIgG or human IgG were used as controls. The results showed that hu6H5 was as effective as m6H5 in killing these breast cancer cells. To further evaluate its effectiveness in cell killing, MDA-MB-231 cells were treated with various antibodies (10 μg / ml) for 16 hours. Live and presumed dead cells were identified using a co-staining viability assay, and the results showed that hu6H5 was as effective as m6H5 in killing breast cancer cells. A cell viability assay was used to evaluate the induction of cell death after anti-HERV-K antibody treatment. MDA-MB-231 cells were seeded overnight in 24-well plates. The cells were treated with various antibodies (10 μg / ml) and incubated for 16 hours at 37°C in a cell culture incubator. Calcein Am (4 μl / 10 ml medium) and Eth-D1 (20 μl / 10 ml medium) were then added at 200 μl per well and cells were incubated for 30 min at room temperature. EthD-1 penetrates cells with membrane damage and binds to nucleic acids resulting in red fluorescence in dead cells. Live cells (green; Calcein Am) and presumed dead cells (red; EthD-1) were identified using a co-stained viability assay. Human IgG or mouse IgG were used as controls. No red fluorescent cells were observed after treatment with control human or mouse IgG. However, red fluorescent cells were observed in cells treated with humanized or mouse 6H5 anti-HERV-K antibodies.
[0189] Using MMT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide), it was confirmed that hu6H5 could inhibit the proliferation of cancer cells. See FIG. 3.
[0190] ADCC was used to determine the mechanism of BC cell killing. Our results support effector cell-mediated secretion of cytotoxic molecules that lyse antibody-coated target cells. ADCC was used to determine the mechanism of antibody-induced cell killing. Greater ADCC lysis of cancer cells was observed in cells treated with hu6H5 than m6H5, and was accompanied by an increased proportion of peripheral blood mononuclear cells.
[0191] Flow cytometry was used to determine whether hu6H5 could downregulate the expression of p-ERK, Ras, and SIRT-1. 231C or 231K cells were treated with 10 μg of hu6H5 per ml for 16 hours. The expression of HERV-K, SIRT-1, p-ERK, and Ras in cells under both membrane-permeabilized and membrane-impermeabilized conditions was examined. Downregulation of the expression of HERV-K, p-ERK, Ras, and SIRT-1 was demonstrated in 231K treated with hu6H5 or 231C. Mice were inoculated with 231K or 231C cells (2 million cells by subcutaneous injection). Mice were then treated with hu6H5 antibody (n=3; 4 mg / kg, twice weekly). Tumor growth was monitored and measured three times a week, and mouse survival was determined. Treatment of mice with hu6H5 resulted in longer survival than a separate cohort of mice treated with a control antibody (n=4). Mice inoculated with 231K cells were observed to have shorter survival times than mice inoculated with 231C cells, indicating that overexpression of HERV-K in breast cancer cells shortens tumor-associated survival.
[0192] pLVXK is the HERV-K expression vector, and MDA-MB-231 pLVXK is MDA-MB-231 cells transduced with pLVXK. Similarly, pLVXC is the control expression vector alone, and MDA-MB-231 pLVXK is MDA-MB-231 cells transduced with pLVXC. NSG female mice (8 weeks old) were inoculated with MDA-MB-231 pLVXC (231-C; subcutaneous, 2 million cells) and separately with MDA_MB-231 pLVXK (231-K; subcutaneous, 2 million cells). On day 6, mice were treated with hu6H5 (4 mg / kg intraperitoneally, twice a week for 3 weeks). Tumor growth was monitored and measured every other day. Higher survival rates were demonstrated in mice bearing antibody-treated 231-C and 231-K cells. Tumor and lung tissue were harvested from each mouse, and larger lymph nodes were detected in some mice bearing 231-K cells but not in those with 231-C cells.
[0193] Further hematoxylin-eosin (H&E) staining was used to evaluate the morphological characteristics of tumor tissues and tissues from other organs (lungs and lymph nodes). Tumor viability and tumor necrosis were quantified by measuring tumor area by H&E staining by a pathologist. Humanized antibody treatment resulted in smaller tumor volume, reduced tumor localization and number, reduced invasive borders, and reduced mitotic activity. Decreased tumor viability was observed in mice bearing 231-C cells or 231-K cells treated with antibodies. Decreased tumor viability was evidenced in 231C or 231K cells treated with hu6H5 compared to controls. Anti-Ki67 and anti-HERV-K mAbs were used. Decreased tumor viability was evidenced in mice treated with hu6H5 (20%) compared to controls (60%). Antibody-treated groups had more homogenous appearance, fewer polymorphic nuclei, smaller nucleoli, and a significantly increased number of tumor-infiltrating lymphocytes.
[0194] Metastatic tumor cells were also found in the lungs from mice bearing 231K cells, but not in mice bearing 231C cells. Metastasis to the lungs or lymph nodes was observed in mice inoculated with 231K cells. Decreased tumor viability and increased tumor necrosis were detected in the lungs of mice inoculated with 231K cells and treated with hu6H5. Macroscopically enlarged lymph nodes were observed in mice inoculated with 231K cells, but not in mice inoculated with 231C cells. Decreased tumor viability and increased tumor necrosis were detected in the lymph nodes of mice inoculated with 231K cells and treated with hu6H5(KAB) (B18; 40%), compared with mice inoculated with 231K cells (KCON) without added antibody (B26 >95%). These results indicate that HERV-K expression is a causative factor in tumor initiation, especially metastasis to distant organ sites. Our humanized anti-HERV-K antibody could decrease tumor viability, increase tumor necrosis, and reduce metastasis to lungs and lymph nodes. Decreased tumor viability was observed in the lungs of mice bearing 231-K treated with the antibody compared to mice not treated with the antibody. Metastatic lymph nodes were only detected in mice inoculated with 231K cells. More than 95% tumor viability was detected in the lymph nodes of mice bearing 231-K cells, and decreased tumor viability was observed in the lymph nodes of mice treated with the antibody compared to mice not treated with the antibody. Ascites was evidenced in mice bearing 231K or 231C tumor cells without antibody treatment. Example 10
[0195] Efficacy of bispecific T cell-engaging antibodies (BiTEs) targeting HERV-K We generated BiTEs directed against T cell CD3 or CD8 and the tumor-associated antigen HERV-K, which were composed of antibodies targeting either CD3 or CD8 and HERV-K. This BiTE was shown to induce interferon gamma (IFNγ) cytotoxic activity against MDA-MB-231 breast cancer cells expressing major histocompatibility class (MHC) molecules loaded with HERV-K epitopes, with a 20- to 30-fold increase in IFNγ expression following treatment with the BiTE (see Figure 4).
[0196] BiTEs are recombinant proteins constructed as single-chain antibody constructs that redirect T cells to tumor cells, without requiring proliferation of endogenous T cells through antigen-presenting cells. BiTE molecules can be administered directly to patients, and BiTE-mediated T cell activation does not depend on the presence of MHC class I molecules, as CARs do. Given that we have successfully targeted HERV-K Env as a tumor-associated antigen (TAA), and that nearly all breast cancer cell lines express Kenv protein, we hypothesize that, like K-CARs, BiTEs specific for Kenv and CD3 (K3Bi) will effectively treat metastatic disease. We designed and synthesized K3Bi with dual specificity for Kenv and CD3. Thus, T cells will target HERV-K+ tumor cells. We generated, purified, and validated K3Bi and CD8 BiTEs (K8Bi). This was done using mAb 6H5, also used in the CAR construct, and OKT3, an antibody against human CD3, used in other BiTEs, which was humanized and connected with a flexible linker with two C-terminal epitope tags (MYC and FLAG) for purification and staining. CD8 single chain antibody (scFv) obtained from OKT8 hybridoma cells was generated in our laboratory and used to generate K8Bi (VL-VH6H5 linker VH-VLCD8-MYC and FLAG). K3Bi and K8Bi were cloned into pLJM1-EGFP Lenti or pGEX-6P-1 vectors for recombinant protein expression. The ability of K3Bi or K8Bi to bind to T cells and HERV-K+ breast cancer cell lines was measured by several immunoassays. We found that increasing BiTE concentration increased the number of target cells that bound to the BiTE.
[0197] We also investigated the ability of K3Bi to induce T cell activation, proliferation, cytokine production, and lysis of target tumor cells. Bulk PBMCs (50,000 per well) from healthy controls were co-cultured with K3Bi (0, 1, 10, 100, and 1,000 ng / ml) and tumor cells (5,000 per well) at an effector:target cell ratio of 10:1 as described in Zhang et al., Cancer Immunol. Immunother., 63, 121-132 (2014). One result is shown in Figure 5. PBMC+ MCF-7 + K3Bi showed increased cancer cell killing compared to PBMC+MCF-7 without K3Bi. See Figure 5A. LDH release assay was used to detect cell viability and cytotoxicity, as we have done previously. See Zhou et al., Oncoimmunology, 4, e1047582 (2015). Increased IFNγ production was observed in MDA-MB-231, MDA-MB-468, and MCF-7 cells treated with K3Bi, as assayed by ELISA. See Figure 5B. Untreated cells, PBMC only, or BiTE only were used as controls, and no IFNγ production was observed in these control groups.
[0198] Treatment of immunodeficient NSG mice bearing HERV-K positive MDA-MB-231 breast cancer cells with PBMCs and CD3 HERV-K BiTE and IL-2, or CD8 HERV-K BiTE and PBMC and IL-2, significantly reduced tumor growth. See Figure 6. 231K cells were also treated separately with hu6H5 and human immunoglobulin G (huIgG) control antibodies and compared. Live / dead cell assay kits (Calcein AM, 7-AAD AD) revealed that 231K cells were increased in death after treatment with hu6H5 compared to control huIgG. Example 11
[0199] Staining results of normal donor PBMCs transduced with CAR-A and CAR-B lentiviral vectors PBMCs from normal donors were transduced with two CAR-T lentiviral vector constructs, K-CAR-A (CAR-A) or K-CAR-B (CAR-B); pWPT-GFP with psPAX2 and pMD2g; VH-VLhu6H5-CD8-CD28-4-1BB-CD3 zeta. An alternative to the Sleeping Beauty transduction process, the protocol to generate HERV-Kenv CAR-T cells by lentiviral transduction, is as follows:
[0200] 1. PBMCs (2 × 10 7 ) and deplete monocytes by plastic adherence (1 hour incubation at 37°C, 5% CO2).
[0201] 2. Culture monocyte-depleted PBMCs in RPMI 1640 supplemented with 10% FBS, 100 U / mL penicillin, and 100 μg / mL streptomycin (complete medium). Stimulate T cells with anti-CD3 / CD28 beads at a bead:cell ratio of 3:1 containing 40 IU / mL IL-2 for 24 hours.
[0202] 3. Transduce activated T cells with CAR-A or CAR-B lentiviral particles (CD19 CAR as a control).
[0203] 4. 24 hours after transduction, culture T cells in complete medium containing 300IU / mL IL-2 and gamma-irradiated (100Gy) MDA-MB-231-Kenv (Kenv is the envelope protein of HERV-K) aAPCs at a 2:1 aAPC / T cell ratio to stimulate CAR-T cell proliferation. Gamma-irradiated K562-CD19 are used as control aAPCs.
[0204] 5. Remove anti-CD3 / CD28 beads on day 5. Replenish CAR-T cells with fresh medium containing IL-2 every 2-3 days.
[0205] 6. Use CAR-T cells if proliferation shows a decline from log phase. CAR-A or CAR-B transduced cells were co-cultured with γ-irradiated (100 Gy) MDA MB231 antigen-presenting cells. Soluble IL-2 cytokine (50 U / ml) was added every other day. On day 14, cells were harvested for staining. First, cells were stained for 20 min at 4 °C using a 1:1000 dilution of BV450 live / dead stain. After 20 min, cells were washed and stained for 30 min at 4 °C with K10-AF 488 protein (1 μg / ml), CD4 Amcyan, CD3 Pe cy7, and goat anti-human IgG Fc AF 594 antibodies according to the manufacturer's recommendations, followed by washing with phosphate-buffered saline. Cells were fixed with 4% PFA for 15–30 min and washed before analysis on a flow cytometer. Samples were positive for green fluorescent protein (GFP) because they were transfected with GFP+CAR-A / CAR-B.
[0206] The percentage of CD4+ cells was determined by gating those populations that were BV450 negative and positive for each color. The percentage of CD4- (referred to as CD8+ cells) was gated by selecting the BV450 negative and CD4Amcyan color negative populations. The results show that the percentage of CAR-A / CAR-B transduced CD4+ PBMCs stained with K10-labeled AF488 protein is higher than the percentage of naive T cells stained with K10-labeled AF488 protein. This represents the staining of CAR-A or CAR-B transduced T cells with HERV-K10 protein.
[0207] T cells expressing lentiviral CAR expression vectors carrying humanized or fully human HERV-K scFvs effectively lyse and kill tumor cells from several cancers. Humanized K-CARs expressed from lentiviral vectors are pan-cancer CAR-Ts. Example 12
[0208] HERV-K-specific humanized chimeric antigen receptor (K-CAR) therapy The inventors have generated a humanized single chain variable (scFv) antibody (Example 1) that binds to an antigen generated from recombinant HERV-K Env surface fusion protein (KSU) (Example 3) and lysates from MDA-MB-231 breast cancer cells. The CAR generated from this humanized scFv is cloned into a lentiviral vector and used in combination with various therapies, including but not limited to K-CAR T cells and checkpoint inhibitors, inflammatory cytokines such as interleukin (IL)-12 and IL-18, oncolytic viruses, and kinase inhibitors (including but not limited to p-RSK, p-ERK). Example 13
[0209] Identification of human therapeutic antibodies (hTAbs) from very rare B cells that exhibit strong target specificity and high sensitivity Generation of fully human therapeutic antibodies from the human adaptive immune system:To directly use B cells from breast cancer patients as a source of high affinity antibodies, we performed indirect ELISA or immunoblot using HERV-K Env recombinant fusion protein. We used this to detect anti-HERV-K Env specific responses from several breast cancer patients. Patients with higher titers of anti-HERV-K antibodies were selected for single B cell assays. PBMCs from breast cancer patients were polyclonally activated as follows: (1) using irradiated 3T3-CD40L fibroblasts for 2 weeks. This method can efficiently stimulate CD40-B cells to proliferate into large numbers of cells with high purity (>90%) and induce antibody secretion. (2) ex vivo using recombinant human IL-21, IL-2, soluble CD40 ligand, and anti-APO1 for 4 days. This second method allows the highest percentage of B cells to secrete antibodies with minimal culture time. IL-21 promotes differentiation into antibody-secreting cells. In vitro IL-2 stimulation can induce differentiation of human plasma cells, which requires T cell help to reach the induction threshold. sCD40L binds to CD40 expressed on the cell surface of B cells to mimic T cell-mediated activation. Anti-APO1 is used to rescue B cells from Fas-induced apoptosis, as activation also induces cell death. Almost no cytotoxic B cells were detected.
[0210] Development of a platform to determine the binding kinetics and cell-cell interactions of individual cells within microwell plates.Details of the microintaglio process, which allows for the screening and monitoring of B cell interactions over time and allows single cell cloning of antibody-producing B cells. Arrays of nanowells were fabricated in polydimethylsiloxane (PDMS) and mammosphere cells from patient breast tumor tissues generated and cultured in our laboratory were used as targets to determine the efficacy of breast cancer cell killing. B cells and mammosphere cells (1:1 ratio) from the same donor were loaded into the nanowell array (1 cell per well) and the cells were allowed to settle by gravity. Dead tumor cells (red) and B cells are represented in the same well. Anti-HERV-K antibodies produced by this B cell were detected at the same position on a glass cover slide. A single B cell was then harvested by CellCelector for RT-PCR. Our results show that HERV-K-specific memory B cells showed anti-HERV-K antibody expression and cytotoxicity against autologous mammosphere cells.
[0211] Therapeutic Antibody Discovery Using In Vivo Enrichment (IVE) Applications: This platform allows the isolation of antibodies that not only bind to target cancer cells but also can kill them. This platform also allows the generation of hTAbs using normal donors without memory B cells instead of breast cancer patient donors. Since B cells capable of producing therapeutic antibodies for treatment are very rare even after ex vivo enrichment, the inventors developed the following platform to identify very rare hTAbs:
[0212] Groups (N=10 / group) of wild-type Balb / c mice (female, 6 weeks old) were immunized on day 1 and boosted on weeks 3 and 5. ELISPOT was used to measure IFNγ secretion by CD8+ T cells from immunized mice (immunized with HERV-K transmembrane (TM) protein (mouse M1-M4) or phosphate-buffered saline (M5-M6)). ELISA assay was used to detect anti-HERV-K IgG titers in immunized mouse sera. Higher antibody titers were detected in mice treated with HERV-K Env surface fusion protein, regardless of CpG or CDN status. HERV-K antibody titers were detected by ELISA using anti-human IgG mAb in human tumor mouse models inoculated with MDA-MB-231 (HTM1) or MDA-MB-468 (HTM2) and in humanized mice immunized with HERV-K surface fusion protein (HM1 and HM2). [Example 13-1]
[0213] We applied in vivo enrichment technology (IVE: enriched approximately 20-fold) in SCID / beige mice to enable rapid proliferation and activation of B cells, generating a large number of antigen-specific plasmablasts. See Figure 4. This platform generates fully human antibodies from B cells in as little as 8 days. As a proof of principle, we developed an in vivo enrichment technique to produce fully human anti-Zika antibodies in hybridoma cells generated from splenocytes on day 8 of fusion with MFP-2 partner cells.
[0214] Recently, humanized mice (HM) and human tumor mice (HTM) have been developed using CD34+ cells (1-2 x 10) for the generation of humanized mice and immunization with HERV-K SU or PD-L1 recombinant fusion proteins. 5 The results were successfully generated by intravenous injection of 100 μg / mouse.
[0215] The present inventors also cultured CD34+ hematopoietic stem cells at 5×10 4 -3x10 6Breast cancer cells were co-implanted with triple-negative breast cancer patient-derived xenografts (TNBC PDX cells, or MDA-MB-231 or MDA-MB-468 TNBC cells) into the mammary fat pad to generate human tumor mice. + The percentage of hCD19 or hCD45 cells was quantified in huCD45+ cells obtained 4 weeks after inoculation of TNBC PDX cells and 7 weeks after inoculation of MDA-MB-231 human tumor mouse models with co-transplantation of CD34+ hematopoietic stem cells. The percentage of hCD19 or hCD45 cells was higher in mice after longer periods of inoculation with CD34 cells. Antigen exposure was associated with HERV-K expression in the tumors, with higher antibody titers detected (HTM2: 40 days vs. HTM1: 30 days). The results indicate that human tumor mice can produce anti-HERV-K antibodies in mice inoculated with breast cancer cells.
[0216] This result encouraged the use of humanized mice or human tumor mice to generate full hTAbs, especially the use of normal donors that have never been exposed to antigen. NSG mice lack T cell, B cell, and NK cell activity and are ideal candidates for establishing humanized mice. Immunofluorescence staining was used to detect the expression of HERV-K in MDA-MB-231 tumors obtained from human tumor mice using anti-HERV-K mAb 6H5. F-actin was used as a control. huCD3+ cells were also detected in tumor tissues. HERV-K antibody titers were detected by ELISA using anti-human IgG mAb in human tumor mouse models inoculated with MDA-MB-231 (HTM1) or MDA-MB-468 (HTM2), and in HM1 and HM2 immunized with HERV-K SU Env protein.
[0217] Mice were subsequently developed that showed higher engraftment of human CD45+ cells than had been seen in previous results, without significant toxicity.
[0218] In Vivo Enrichment Protocol 1.For tumor-bearing donors with higher antibody titers, we use a protocol that uses humanized mice instead of the standard SCID / beige mice. PBMCs (50x10 6 ) are polyclonally activated with IL-21, IL-2, soluble CD40 ligand and anti-APO1 and premixed with antigen (HERV-K or PD-L1; 100 μg). B cells isolated from the above PBMCs by negative selection using the EasySep® Human B Cell Enrichment Kit (Stemcell Technologies) are co-injected with CD34 cells into mice treated with busulfan (Fisher: 30 mg / kg i.p.) on day 0. Mice are treated with a cytokine cocktail (days 1, 4, 7) and boosted with antigen on day 2. This protocol can be completed relatively quickly (8 days).
[0219] In Vivo Enrichment Protocol 2 For normal donors without cancer and without memory B cells, we use a modified In Vivo Enrichment Protocol 1: Mice are treated with a cytokine cocktail (days 1, 7, and 14) and boosted with antigen on days 14 and 21. Serum is collected from the mice and binding affinity is tested by ELISA. After an increase in antibody titer is detected, spleens are harvested, analyzed, and used to generate hybridomas. Higher antibody titers were detected at week 2 in mice using In Vivo Enrichment Protocol 2. [Example 13-2]
[0220] Half of the spleen is then harvested for flow cytometric analysis, microintaglio and other analyses. Flow cytometric analysis of B cell surface and intracellular markers and CFSE labeling (Invitrogen CellTrace CFSE kit) is performed using: anti-CD19 PECy5, anti-CD27 allophycocyanin, anti-CD38 PECy7, anti-IgG FITC, or anti-IgM PE isotype control of mouse IgG1k conjugated with FITC, PE, PECy5, PECy7, Alexa 700, or allophycocyanin (all from BD Bioscience). Total CD19+ B cells are isolated from spleens using negative magnetic immunoaffinity bead separation (Miltenyi Biotec) and stimulated with CpG2006 (10 ng / ml; Oligos, Inc.) for 72 h in the presence of recombinant human B cell activating factor (BAFF; 75 ng / ml; GenScript), IL-2 (20 IU / ml), IL-10 (50 ng / ml), and IL-15 (10 ng / ml) (all from BD Biosciences). Tumoricidal B cells obtained directly from protocol 1 or protocol 2 are determined using our multiwell microintaglio platform (up to 400,000 wells) with autologous tumor cells or HERV-K+ TNBC cells as target cells. Cells that not only produce antibodies but also can bind antigens and kill cancer cells are determined. [Example 13-3]
[0221] Next, we developed human hybridoma cells to ensure long-term antibody availability. To develop fully human hybridomas, MFP-2 cells are used as partners and ClonaCell®-HY (Stemcell Technologies Inc.) is used according to its protocol to generate hybridomas in the remaining half of the spleen. Polyethylene glycol (PEG) is used for the fusion of human lymphocytes and MFP-2 cells, and the methylcellulose-based semi-solid medium of this kit is used for cloning and selection of hybridoma cells. Clones grown after selection are pipetted into 96-well plates and screened for reactivity against HERV-K Env protein by ELISA. The isotype of positive clones is determined using a human IgG antibody isotyping kit from Thermo Fisher Scientific. The clones are then adapted to serum-free medium conditions and grown. Hybridoma supernatants are collected and antibodies are purified using Hi-Trap Protein A or Protein G columns depending on the isotype of the human antibody. Protein A columns have high affinity for antibodies of isotype IgG1, IgG2, and IgG4 and show variable binding to antibodies of isotype IgM, whereas Protein G columns show high binding to antibodies of isotype IgG1, IgG2, IgG3, and IgG4 but do not bind IgM antibodies. [Example 13-4]
[0222] We have evaluated the antitumor efficacy of candidate B cells obtained from the above protocol in vitro, including effects on cell growth, proliferation, and apoptosis, as is routinely done in our laboratory. In vivo studies to evaluate the efficacy of hTAbs in immunodeficient mouse models are also performed to evaluate efficacy using breast cancer cell lines and primary tumor cells, compared with non-lesioned, matched control breast cells. Example 14
[0223] Combination therapy Our breast cancer data strongly support the use of combination therapeutic approaches involving HERV-K. Thus, humanized and fully human antibodies targeting HERV-K should enhance the therapeutic efficacy of checkpoint inhibitor antibodies. Effective cancer combination therapies include, but are not limited to, the following combinations: (a) HERV-K hTAb (1.5 mg / kg), (b) K-CAR, (c) K-BiTE, (d) HERV-K shRNA or CRISPR / Cas9 genome editing technology to knock down HERV-K gene expression, (e) or prophylactic or therapeutic HERV-K vaccines such as full-length and truncated HERV-K Env proteins and HERV-K Env peptides, and (a) anti-ICP antibodies, (b) cancer chemotherapy, (c) 5-azacytidine, 5-aza-2'-deoxycytidine, or other epigenetic modulators such as DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi), (d) EMT inhibitors, (e) inhibitors of cell migration or invasion, (f) induction of S-phase or G2-phase cell cycle arrest, (g) or combinations of HERV-K shRNA and K-CAR with K-BiTE, (h) or combinations of K-BiTE with K-BiTE, (i) or combinations of K-BiTE with K-BiTE, (j) or combinations of K-BiTE with K-BiTE, (j) or combinations of K-BiTE with K-BiTE, (k) or combinations of K-BiTE with K-BiTE, (k) or combinations of K-BiTE with K-BiTE, (l ... Inhibitors of the PI3K / AKT / mTOR or MAPK / ERK signaling pathways, or (h) signaling to HIF1α.
[0224] We used a combination of HERV-K and immune checkpoint assays to assess baseline immune status in breast cancer patients in relation to HERV-K status. Expression of soluble immune checkpoint proteins was determined in breast cancer patients, including DCIS and invasive breast cancer, versus normal donors using Luminex assays. We compared the expression of six ICPs in DCIS, invasive breast cancer (aBC), and normal female donors. A notable finding was that the expression of six circulating ICPs was significantly enhanced in the plasma of breast cancer patients. An additional finding was a significant decrease in immune checkpoint protein levels in patients 6 or 18 months after surgery compared to before surgery (time point 1). A clear association was observed between soluble ICP molecule levels and HERV-K antibody titers induced by HERV-K expression in tumors. This result suggests that HERV-K antibody titers may affect ICP levels in breast cancer. Thus, HERV-K expression may control the immune response in breast cancer patients. Example 15
[0225] Sequence data Anti-CD3 and CD8 BiTE Table 3 Anti-CD8 heavy chain alignment H3 TNTCAGGTGCAGCTGAAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTCAAG 60 H6 TTTGAGGTCCAGCTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTCAAG 60 H7 --TCAGGTCCAACTGCAGCAGCCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTCAAG 58 H1 TTTGAGGTCCAGCTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTCAAG 60 * **** **.***.***** ************************************** H3 TTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATACACTTCGTGAGGCAG 120 H6 TTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATACACTTCGTGAGGCAG 120 H7 TTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATACACTTCGTGAGGCAG 118 H1 TTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATACACTTCGTGAGGCAG 120 ********************************************************** H3 AGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGATAATACTTTA 180 H6 AGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGATAATACTTTA 180 H7 AGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGATAATACTTTA 178 H1 AGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGATAATACTTTA 180 ********************************************************** H3 TATGCCTCAAAGTTCCAGGGCAAGGCCACTATAACAGCAGACACATCATCCAACACAGCC 240 H6 TATGCCTCAAAGTTCCAGGGCAAGGCCACTATAACAGCAGACACATCATCCAACACAGCC 240 H7 TATGCCTCAAAGTTCCAGGGCAAGGCCACTATAACAGCAGACACATCATCCAACACAGCC 238 H1 TATGCCTCAAAGTTCCAGGGCAAGGCCACTATAACAGCAGACACATCATCCAACACAGCC 240 ********************************************************** H3 TACATGCACCTCTGCAGCCTGACATCTGGGGACACTGCCGTCTATTACTGTGGTAGAGGT 300 H6 TACATGCACCTCTGCAGCCTGACATCTGGGGACACTGCCGTCTATTACTGTGGTAGAGGT 300 H7 TACATGCACCTCTGCAGCCTGACATCTGGGGACACTGCCGTCTATTACTGTGGTAGAGGT 298 H1 TACATGCACCTCTGCAGCCTGACATCTGGGGACACTGCCGTCTATTACTGTGGTAGAGGT 300 *********************************************************** H3 TATGGTTACTACGTATTTGAC-CACTGGGGCCAAGGCACCAC---TCTCACANTNNCNNN 356 H6 TATGGTTACTACGTATTTGAC-CACTGGGGCCAAGGCACCAC---TCTCACANTNNCNNN 356 H7 TATGGTTACTACGTATTTGAC-CACTGGGGCCAAGGCACCAC---TCTCACATNTNNNTN 354 H1 TATGGTTACTACGTATTTGACTCACTTGGGCCAAGGCNNTNNNNNTNNCANNNTNNNNNN 360 ********************* **** *********** .**...* *.* H3 N - 357 (Accession No.: 23) H6 A - 357 (Accession No.: 25) H7 -- 354 (Accession No.: 27) H1 NN 362 (Accession No.: 21) Table 4 Anti-CD8 light chain alignment K4 TTTTGACATTGTGCTGACCCAATCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGC 60 K6 TNTTGATATTGTGCTAACTCAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGC 60 K8 ---TGACATCCAGCTGACTCAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGC 57 *** **:***.** **.*************************************** K4 CACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTG 120 K6 CACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTG 120 K8 CACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTG 117 ********************************************************** K4 GAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATCTATCTTGTATCCAACCTAGA 180 K6 GAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATCTATCTTGTATCCAACCTAGA 180 K8 GAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATCTATCTTGTATCCAACCTAGA 177 ************************************************************ K4 ATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACAT 240 K6 ATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACAT 240 K8 ATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACAT 237 *********************************************************** K4 CCATCCTGTGGAGGAGGAGGATGCTGCA-ACCTATTA-CTGTCAGCACATTA-GGGAGCT 297 K6 CCATCCTGTGGAGGAGGAGGATGCTGCA-ACCTATTA-CTGTCAGCACATTA-GGGAGCT 297 K8 CCATCCTGTGGAGGAGGAGGATGCTGCTGACCTATTAGCTGTCAGCACATTATGGGAGCT 297 ***************************: ******** ************* ******* K4 TACACGTTCGGAGGGGGACCAAGCNNNNNNN--- 328 (SEQ ID NO: 29) K6 TACACGNNGANAANNNNNNNNNNCNNNNTNNNNN 331 (SEQ ID NO: 31) K8 TACACGTTCGGNNNNNTNNCTNNTNCNNNNNNNC 331 (SEQ ID NO: 33) ******:
[0226] IgG domain order: VL-VH6H5---VH-VLhuCD3 or CD8 + c-myc tag + FLAG or VL-VHhu6H5---VH-VLhuCD3 or huCD8 + c-myc tag + FLAG. CD8 BiTE See SEQ ID NOs: 35-36. CD3 BiTE See SEQ ID NOs: 37-38.
[0227] Mice were immunized with the five MAPs, and serum was collected and tested by ELISA using various HERV fusion proteins. Only HERV-K surface fusion proteins were positive. Hybridoma cells were generated from mice immunized with the five MAPs, and scFvs were selected. For the scFv against MAPs of HERV-K (sequence of anti-HERV-K mAb), see SEQ ID NO: 45-46. Example 16
[0228] Humanized antibodies targeting HERV-K can be used as antibody-drug conjugates to deliver drugs to cancer cells and tumors Delivery of recombinant gelonin toxin (r-Gel) was observed in HERV-K positive cancer cells using an anti-HERV-K 6H5-rGel antibody drug conjugate.
[0229] Recombinant gelonin (r-Gel) toxin was conjugated with 6H5. Surface and cytoplasmic expression of HERV-K in DOV13 ovarian cancer cells was detected using anti-HERV-K 6H5 mAb. After 4 hours of treatment, r-Gel expression was detected in DOV13 cells using anti-rGel antibody. After 1 hour of internalization using anti-r-Gel antibody, HERV-K env protein or r-Gel signal was detected in OVCAR3, SKBr3, MCF-7, and MDA-MB-231 cells. We observed colocalization of HERV-K env protein and rGel toxin in the cytoplasm of target cells. Antitumor effects were compared in mice inoculated with MDA-MB-231 cells treated with 6H5 (p=0.0052) and 6H5-r-Gel (p<0.0001) compared with mice treated with control IgG.
[0230] Gold nanoparticles (GNPs) in MDA-MB-231 cells were detected by transmission electron microscopy (TEM) after 2 h of incubation with bare gold nanoparticles or 6H5-GNPs. Using a silver-enhanced assay, gold nanoparticles were detected in MDA-MB-231 or SKBr3 tumors isolated from mice 24 h after intravenous injection of 6H5-GNPs or 6H5scFV-GNPs. Gold nanoparticles generate heat when placed in a radio frequency field, killing targeted tumor cells. Example 17
[0231] In vivo imaging of anti-HERV-K antibodies in tumor nodules in mice In vivo imaging using the Nuance system detected higher densities of 6H5 in tumor nodules in mice 24 hours after intravenous injection of the anti-HERV-K-Alexa647 conjugate 6H5-Alexa647.
[0232] LIST OF EMBODIMENTS Specific compositions and methods of HERV-K antibody therapeutics. The scope of the present invention should be defined solely by the claims. Those skilled in the biomedical arts will interpret all claim terms in the broadest possible manner consistent with the context and spirit of the present disclosure. The detailed description herein is illustrative and not limiting or exhaustive. The present invention is not limited to the specific methodology, protocols, and reagents described herein, which may vary in practice. When the specification or claims recite ordered steps or functions, alternative embodiments may perform those functions in a different order or substantially simultaneously. As those skilled in the biomedical arts will recognize, other equivalents and modifications beyond those already described are possible without departing from the inventive concepts described herein.
[0233] All patents and publications cited throughout this specification are incorporated by reference to disclose and describe the materials and methods used in the technology described herein. Such patents and publications are provided solely for their disclosure prior to the filing date of this specification. All statements as to disclosure and publication dates of patents and publications are from the information and belief of the inventors. The inventors make no admission as to the accuracy of the contents or dates of these documents. In the event of a discrepancy between the dates set forth in this specification and the actual publication dates, the actual publication dates shall control. The inventors may have antedated such disclosures by prior invention or for another reason. In the event of a discrepancy between the scientific or technical teachings of an earlier patent or publication and this specification, the teachings of this specification and these claims shall control.
[0234] Where this specification provides a range of values, unless the context dictates otherwise, each value between the upper and lower limits of that range is within the range of values.
[0235] Among the embodiments provided herein are the following: 1.An isolated antibody that binds to human endogenous retrovirus K (HERV-K) and contains a heavy chain variable region (HCVR) and a light chain variable region (LCVR). Humanized anti-HERV-K antibodies reduce tumor growth and metastasis, particularly to the lungs, lymph nodes, and other organs. 2. An antibody according to embodiment 1, comprising a humanized or human framework region. 3. The antibody of embodiment 1, wherein the antibody is a HERV-K antagonist. 4. An isolated nucleic acid comprising a nucleotide sequence encoding the HCVR, LCVR or combination thereof of embodiment 1. 5. An expression vector comprising the nucleic acid of embodiment 4. 6. A host cell transformed with the expression vector of embodiment 5. 7. A method for producing an antibody comprising an HCVR, LCVR, or a combination thereof, comprising: growing a host cell of embodiment 1 under conditions such that said host cell expresses an antibody comprising an HCVR, LCVR, or a combination thereof; and isolating the antibody comprising an HCVR, LCVR, or a combination thereof. 8. A method for treating cancer in a mammal, comprising administering to a mammal in need thereof an effective amount of the antibody of embodiment 1. 9. A method of treating cancer, comprising administering to an individual in need thereof an effective amount of an antibody-drug conjugate comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises CDR1, CDR2, and CDR3, and the VL region comprises CDR1, CDR2, and CDR3, and wherein the antibody is linked via a linker to a cytotoxic agent, an auristatin, or a functional peptide analog or derivative thereof. 10. The method of embodiment 9, wherein the antibody drug conjugate is administered in combination with one or more additional therapeutic agents. 11. The method of embodiment 9, wherein the one or more therapeutic agents comprises a chemotherapeutic agent. 12. The method of embodiment 9, wherein the cancer is selected from the group consisting of melanoma, chronic lymphocytic leukemia, breast cancer, pancreatic cancer, head and neck cancer, ovarian cancer, cervical cancer, colorectal cancer, testicular cancer, gastric cancer, renal cancer, endometrial cancer, uterine cancer, bladder cancer, prostate cancer, esophageal cancer, liver cancer, and non-small cell lung cancer. 13. Humanized antibodies developed for CAR T, CAR NK, and BiTE research. 14. The method of embodiment 9, wherein the antibody is a full-length antibody. 15. The method of embodiment 9, wherein the antibody is a human monoclonal IgG1 or IgG4 antibody. 16. The method of embodiment 9, wherein the auristatin is monomethylauristatin E (MMAE) or monomethylauristatin F (MMAF). 17. The method of embodiment 9, wherein the cytotoxic agent is emtansine (DM1); ozagamycin (calicheamicin); deruxtecan (DXd); govitecan (SN-38); mafodotin (MMAF); duocarmazine (duocarmycin); BAT8001 (maytansinoid); sorafutansine (DM4); or tesirin (PBD). 18. The method of embodiment 9, wherein the linker is attached to a sulfhydryl residue of the antibody obtained by partial reduction of the antibody. 19. The method of embodiment 9, wherein the linker-auristatin is vcMMAF or vcMMAE. 20. An early detection, metastasis, or HERV-K and immune checkpoint biomarker, substantially as described herein. 21. Cancer cells overexpressing HERV-K as targets for the anti-HERV-K humanized antibodies and antibody-drug conjugates of the present invention. 22. hu6H5 clones generated from bacteria (HUM1 and HUM2) or mammalian cells (FWJ1 and FWJ2). 23. BiTEs against T cell CD3 or CD8, including antibodies targeting either CD3 or CD8 and HERV-K, and a humanized scFv against the tumor-associated antigen HERV-K. 24. T cells expressing a lentiviral CAR expression vector carrying a humanized or fully human HERV-K scFv. 25. A humanized single-chain variable region (scFv) antibody capable of binding to antigen generated from recombinant HERV-K Env surface fusion protein (KSU) and to lysates from cancer cells expressing HERV-K Env protein. 26. A CAR made from the humanized scFv of embodiment 28, optionally cloned into a lentiviral vector. 27. A CAR made from the humanized scFv of embodiment 28, which is cloned into a CAR for use in combination therapy. 28. An improved in vivo enrichment method for rapid expansion and B cell activation for donors with no memory B cells, comprising treating mice with a cytokine cocktail on days 1, 7, and 14, and boosting the mice with antigen on days 14 and 21. 29. Cells that not only produce antibodies, but also can bind to the antigen and kill cancer cells, and cells that express the antigen can be killed by the antibody. 30. Significantly enhanced expression of six circulating immune checkpoint proteins in the plasma of breast cancer patients. 31. A method of inhibiting the immunosuppressive domain (ISD) of HERV-K using immune checkpoint inhibitors. 32. The method of embodiment 31, wherein the HERV-K immune checkpoint inhibitor is selected from the group consisting of monoclonal antibodies and drugs targeting the ISD of HERV-K. 33. Humanized and fully human antibodies targeting HERV-K used to enhance the efficacy of checkpoint inhibitor antibody therapy. 34. A method to produce new antibodies from mice immunized with five types of multiple antigen peptides (MAPS) generated from the HERV-K SU protein produced by cancer patients. 35. Method for producing HERV-K CAR A: VH-VLhu6H5-CD8-CD28-4-1BB-CD3 zeta. References Those skilled in the art of molecular biology may use these patents, patent applications, and scientific references as guides to predictable results in making and using the present invention: Patent literature: US Pat. No. 9,243,055 (Wang-Johanning). This patent discloses and claims the diagnosis and treatment of cancer. Methods and compositions are provided for detecting, preventing, and treating HERV-K+ cancers. One method is to prevent or inhibit cancer cell proliferation by administering to a subject an amount of a HERV-K env protein binding antibody that prevents or reduces cancer cell proliferation. US Pat. No. 10,723,787 International Pat. Publ. WO 2010 / 138803 (Board of Regents, the University of Texas System) discloses an isolated antibody that binds to human endogenous retrovirus K (HERV-K), comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR). (The HERV-K protein recognized by an antibody with a light chain variable region and a heavy chain variable region). International Pat. Publ. WO 2014 / 186469 (Board of Regents, the University of Texas System). This patent publication relates to methods and compositions for immunotherapy using engineered T cells containing chimeric antigen receptors (CARs). CAR-expressing T cells are generated using electroporation in conjunction with a transposon-based integration system to generate a population of CAR-expressing cells that require minimal ex vivo expansion or can be administered directly to patients for cancer treatment. International Pat. Publ. WO 2019 / 104037 A1 (The Brigham and Women's Hospital, Inc.) Scientific literature: Burstein & Winer, Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J. Clin Oncol., 27, 5671-5673 (2009). Buscher et al., Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res., 65, 4172-4180 (2005). Cao, Human endogenous retroviruses in clear cell renal cell carcinoma: biological functions and clinical values." Duvtlμress Web (August 7, 2020). Chae et al., Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci Rep., 8, 2918 (2018). Chiappinelli et al., Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell., 162, 974-986 (2015). Choi et al., Human B cell development and antibody production in humanized NOD / SCID / IL-2Rgamma(null) (NSG) mice conditioned by busulfan. J. Clin Immunol., 31, 253-264 (2011). Denne et al., Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J. Virol., 81, 5607-5616 (2007). Downey et al., Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice? Int. J. Cancer, 137, 1249-1257 (2015). Ejthadi et al., A novel multiplex RT-PCR system detects human endogenous retrovirus-K in breast cancer. Arch Virol., 150, 177-184 (2005). Elgueta et al., Molecular mechanism and function of CD40 / CD40L engagement in the immune system. Immunol Rev., 229, 152-172 (2009). Etkind, Lumb, Du, & Racevskis, Type 1 HERV-K genome is spliced into subgenomic transcripts in the human breast tumor cell line T47D. Virology., 234, 304-308 (1997). Ettinger et al., IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol., 175, 7867-7879 (2005). Feldhaus et al., Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nature Biotechnol., 21, 163-170 (2003). Fischer et al., Human endogenous retrovirus np9 gene is over expressed in chronic lymphocytic leukemia patients. Leuk. Res. Rep., 3, 70-72 (2014). Gonzalez-Cao et al., Human endogenous retroviruses and cancer. Cancer Biol. Med., 13, 483-488 (2016). Good, Bryant, & Tangye, Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J. Immunol., 177, 5236-5247 (2006). Grandi, HERV envelope proteins: Physiological role and pathogenic potential in cancer and autoimmunity. Frontiers in Microbiology. Web (March 14, 2018). Helsen et al. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nature Commun., 9, 3049 (2018). Herve et al., Autoantibodies to human endogenous retrovirus-Kare frequently detected in health and disease and react with multiple epitopes (April 28, 2002) discloses antibodies specific to HERV-K (autoantibodies specific to HERV-K). Hipp et al., IL-2 imprints human naive B cell fate towards plasma cell through ERK / ELK1-mediated BACH2 repression. Nature Commun., 8, 1443 (2017). Hughes & Coffin, Evidence for genomic rearrangements mediated by human endogenous retroviruses during primate evolution. Nature Genetics, 29, 487-489 (2001). HERVs originated from thousands of ancient integration events which incorporated retrovirus DNA into germline cells. Johanning et al., Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Science Reports, 7, 41960 (2017). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. They also found that the expression of HERV-K env transcripts in breast cancer was specifically associated with basal breast cancer, an aggressive subtype. Kleiman et al. HERV-K(HML-2) GAG / ENV antibodies as indicator for therapy effect in patients with germ cell tumors. Int. J. Cancer, 110, 459-461 (2004). Koncz & Hueber, The Fas / CD95 receptor regulates the death of autoreactive B Cells and the selection of antigen-specific B cells. Front Immunol., 3, 207 (2012). Kontermann & Brinkmann, Bispecific antibodies. Drug Discov. Today (2015). Kontsekova et al., First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res. Ther., 6, 44 (2014). Kraus et al. Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system. PLoS One, 8, e72756 (2013). Krishnamurthy et al., Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clin Cancer Res., 21, 3241-3251 (2015). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Lander et al. Initial sequencing and analysis of the human genome. Nature, 409, 860-921 (2001). HERVs are well-known as genomic repeat sequences, with many copies in the genome, such that approximately 8% of the human genome is of retroviral origin. Lanzavecchia, Corti, & Sallusto, Human monoclonal antibodies by immortalization of memory B cells. Current Opinion Biotechnol., 18, 523-528 (2007). Larsson, Kato, & Cohen, Human endogenous proviruses. Current Topics Microbiol. Immunol., 148, 115-132 (1989). The most biologically active HERVs are members of the HERV-K family. HERV-K has a complete sequence capable of expressing all the elements needed for a replication-competent retrovirus. Lemaitre et al, human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion. PLoS Pathog., 13, e1006451 (2017). Li et al., Down-regulation of human endogenous retrovirus type K (HERV-K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth. Clinical Cancer Research, 23, 5892-5911 (2017). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Liu et al., Structure-based programming of lymph-node targeting in molecular vaccines. Nature., 507, 519-522 (2014). Maldini, Dual CD4-based CART cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo 1. Nature Medicine Web (August 31, 2020). Mazor et al., Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nature Biotechnol., 25, 563-565 (2007). Meijer et al., Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol Biol., 358, 764-772 (2006). Morozov, Dao Thi, & Denner, The transmembrane protein of the human endogenous retrovirus--K (HERV-K) modulates cytokine release and gene expression. PLoS One., 8, e70399 (2013). Natsume, Niwa, & Satoh, Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des. Devel. Ther., 3, 7-16 (2009). Novak et al., Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol., 16, 123-134 (2017). Ono, Kawakami, & Ushikubo, Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J. Virol., 61, 2059-2062 (1987). Ono, Yasunaga, Miyata, & Ushikubo, Nucleotide sequence of human endogenous retrovirus genome related to the mouse mammary tumor virus genome. J. Virol. 60, 589-598 (1986). The most biologically active HERVs are members of the HERV-K family. HERV-K has a complete sequence capable of expressing all the elements needed for a replication-competent retrovirus. Oricchio et al., Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. Oncogene, 26, 4226-4233 (2007). Robinson-McCarthy et al., Reconstruction of the cell entry pathway of an extinct virus. PLoS Pathog., 14, e1007123 (2018). Rycaj et al., Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells. Clin Cancer Res., 21, 471-483 (2015). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Scheid et al., Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 458, 636-640 (2009). Seifarth et al., Retrovirus-like particles released from the human breast cancer cell line T47-D display type B- and C-related endogenous retroviral sequences. J. Virol., 69, 6408-6416 (1995). Seitz et al., Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues. Proc. Natl. Acad. Sci. U.S.A., 103, 12057-12062 (2006). Serafino et al., The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp. Cell Res., 315, 849-862 (2009). Smith et al., Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nature Protoc., 4, 372-384 (2009). Song & Liu, A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms. Science Reports., 5, 12578 (2015). Spector & Blackwell, Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin Oncol., 27, 5838-5847 (2009). Wallace et al., Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. Carcinogenesis., 35, 2074-2083 (2014). Wang-Johanning et al., Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma. Cancer, 98, 187-197 (2003). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Wang-Johanning et al., Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clinical Cancer Res. 7, 1553-1560 (2001). Wang-Johanning et al., Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int. J. Cancer., 120, 81-90 (2007). Wang-Johanning et al., Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res., 68, 5869-5877 (2008). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Wang-Johanning et al., Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. Int. J. Cancer., 134, 587-595 (2014). Wang-Johanning et al., Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J. Natl Cancer Inst., 104, 189-210 (2012). The inventors showed that the HERV-K Env protein is commonly expressed on the surface of breast cancer cells. The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors 30-34. Wang-Johanning et al., Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene, 22, 1528-1535 (2003). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Wang-Johanning et al., Tumor microenvironment predicts aggressive breast cancer: Combination of HERV-K, immune checkpoint and activation status of CD8+ T cells. Cancer Res., 77, Abstract nr LB-221 (2017). Zahavi, Monoclonal Antibodies in Cancer Therapy. MDPI Web. (July 20, 2020). Zhang et al., An EpCAM / CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunol. Immunother., 63, 121-132 (2014). Zhao et al. Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer. Genes Cancer., 2, 914-922 (2011). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Zhou et al., Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells. Oncotarget, 7, 84093-84117 (2016). Zhou et al., Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras. Oncoimmunology, 4, e1047582 (2015). The inventors observed the expression of HERVs, especially HERV-K sequences, in breast, lung, prostate, ovarian, colon, pancreatic, and other solid tumors. Zhou, Zou, Zhang, & Marks, Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J. Mol Biol., 404, 88-99 (2010). Sequence Listing SEQ ID NO: 1 Sequence of mouse ScFV gene VH-linker-VL ATGGCCCAGGTGAAGCTGCAGCAGTCAGGACCTGACCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGGCGTCTGGTTACTCATTCACTGGCTACTACATGCACTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGACGTGTTAATCCTAACAGTGGTGGTACAAGCTACAACCAGAAGTTCAAGGACAAGGCCATATTAACTGTAGACAAGTCATCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGATCGAAAGGTAACTACTTC TATGCTATGGACTACTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAAGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATCGAGCTCACTCAGTCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGCAGAGCCAGTGAAAGTGTTGATAGTCATGGCACTAGTTT TATGCACTGGTACCAGCAGAAACCAGGACAGCCACCCAAATTCCTCATCTATCGTGCATCCAACCTAGAATCTGGGATCCCTGCCAGGTTCAGTGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATTAATCCTGTGGAGACAGATGATGTTGCAATCTATTACTGTCAGCAAAGTAATGAGGATCCTCCGACGTTCGG TGGAGGCACCAAGCTGGAAATCAAAC SEQ ID NO: 2 Mouse ScFV gene: VH sequence CAGGTGAAGCTGCAGCAGTCAGGACCTGACCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGGCGTCTGGTTACTCATTCACTGGCTACTACATGCACTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGACGTGTTAATCCTAACAGTGGTGGTACAAGCTAC AACCAGAAGTTCAAGGACAAGGCCATATTAACTGTAGACAAGTCATCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGATCGAAAGGTAACTACTTCTATGCTATGGACTACTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAA SEQ ID NO: 3 Mouse ScFV gene: VH sequence CDR is highlighted QVKLQQSGPDLVKPGASVKISKASGYSFTGYYMHWVKQSHGKSLEWIGRVNPNSGGTSYNQKFKDKAILTVDKSSSTAYMELRSLTSEDSAVYYCARSKGNYFYAMDYWGQGTTVTVSS SEQ ID NO: 4 Mouse ScFV gene: VL sequence GACATCGAGCTCACTCAGTCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGCAGAGCCAGTGAAAGTGTTGATAGTCATGGCACTAGTTTTATGCACTGGTACCAGCAGAAACCAGGACAGCCACCCAAATTCCTCATCTATCGTGCATC CAACCTAGAATCTGGGATCCCTGCCAGGTTCAGTGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATTAATCCTGTGGAGACAGATGATGTTGCAATCTATTACTGTCAGCAAAGTAATGAGGATCCTCCGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAAC SEQ ID NO: 5 Mouse ScFV gene:>FWJ_VL sequence CDR is highlighted DIELTQSPASLAVSLGQRATISCRASESVDSHGTSFMHWYQQKPGQPPKFLIYRASNLESGIPARFSGSGSRTDFTLTINPVETDDVAIYYCQQSNEDPPTFGGGTKLEIK SEQ ID NO: 6 Humanized ScFV gene: HUM1-FWJVH sequence EVQLVESGGGLVQPGGSLRLSCKASGYSFTGYYMHWVRQAPGKGLEWIGRVNPNSGGTSYNQKFKDRATLSVDNSKNTAYLQMNSLRAEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSS SEQ ID NO: 7 Humanized ScFV gene:>HUM2_FWJ_VH sequence EVQLVESGGGLVQPGGSLKVSCKASGYSFTGYYMHWVRQASGKGLEWIGRVNPNSGGTSYNQKFKDRFTISRDKSISTLYLQMSSLRSEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSS SEQ ID NO: 8 Mouse ScFV gene:>FWJ_VH sequence QVKLQQSGPDLVKPGASVKISKASGYSFTGYYMHWVKQSHGKSLEWIGRVNPNSGGTSYNQKFKDKAILTVDKSSSTAYMELRSLTSEDSAVYYCARSKGNYFYAMDYWGQGTTVTVSS SEQ ID NO: 9 Humanized ScFV gene:>HUM1_FWJ_VL sequence DIQMTQSPSSLSASVGDRVTITCRASESVDSHGTSFMHWYQQKPGKAPKFLIYRASNLESGIPSRFSGSGSGTDFTLTISSVQPEDFAVYYCQQSNEDPPTFGGGTKVEIK SEQ ID NO: 10 Humanized ScFV gene:>HUM2_FWJ_VL sequence DIQMTQSPSSLSASVGDRVTISCRASESVDSHGTSFMHWYQQKPGKSPKFLIYRASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSNEDPPTFGGGTKVEIK SEQ ID NO: 11 Mouse ScFV gene:>FWJ_VL sequence DIELTQSPASLAVSLGQRATISCRASESVDSHGTSFMHWYQQKPGQPPKFLIYRASNLESGIPARFSGSGSRTDFTLTINPVETDDVAIYYCQQSNEDPPTFGGGTKLEIK SEQ ID NO: 12 Final humanized version of scFv gene scFv-1 EVQLVESGGGLVQPGGSLRLSCKASGYSFTGYYMHWVRQAPGKGLEWIGRVNPNSGGTSYNQKFKDRATLSVDNSKNTAYLQMNSLRAEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSSGGG GSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASESVDSHGTSFMHWYQQKPGKAPKFLIYRASNLESGIPSRFSGSGSGTDFTLTISSVQPEDFAVYYCQQSNEDPPTFGGGTKVEIK SEQ ID NO: 13 Final humanized version of scFv gene scFv-2 EVQLVESGGGLVQPGGSLKVSCKASGYSFTGYYMHWVRQASGKGLEWIGRVNPNSGGTSYNQKFKDRFTISRDKSISTLYLQMSSLRSEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSSGGG GSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTISCRASESVDSHGTSFMHWYQQKPGKSPKFLIYRASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSNEDPPTFGGGTKVEIK SEQ ID NO: 14 Standard 17 amino acid linker SSGGGGSGGGGSGGGGS SEQ ID NO: 15 Final humanized version of the scFv gene: humanized scFv-1 FWJ_HUMscFv-1 EVQLVESGGGLVQPGGSLRLSCKASGYSFTGYYMHWVRQAPGKGLEWIGRVNPNSGGTSYNQKFKDRATLSVDNSKNTAYLQMNSLRAEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSSGGG GSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASESVDSHGTSFMHWYQQKPGKAPKFLIYRASNLESGIPSRFSGSGSGTDFTLTISSVQPEDFAVYYCQQSNEDPPTFGGGTKVEIK SEQ ID NO: 16 Final humanized version of the scFv gene: Humanized scFv-1_Polynucleotide (HUM1) GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCTGCAAGGCCAGCGGCTACAGCTTCACCGGCTACTACATGCACTGGGTGAGGCAGGCCCCCGGCAAGGGCCTGGAGTGGATCGGCAGGGTGAACCCCAACAGCGGCGGCACCAGCTACAACCAGAAGTTCAAGGACAGGGCCACCCTGAGCGTGGACAACAGCAAGAACACCGCCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGAGCAAGGGCAACTACTTCTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACCATCACCTGCAGGGCCAGCGAGAGCGTGGACAGCCACGGCACCAGCTTCATGCACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGTTCCTGATCTACAGGGCCAGCAACCTGGAGAGCGGCATCCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCGTGCAGCCCGAGGACTTCGCCGTGTACTACTGCCAGCAGAGCAACGAGGACCCCCCCACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG Accession number: 18 Final humanized version of the scFv gene: Humanized FWJ_HUMscFv-2 EVQLVESGGGLVQPGGSLKVSCKASGYSFTGYYMHWVRQASGKGLEWIGRVNPNSGGTSYNQKFKDRFTISRDKSISTLYLQMSSLRSEDTAVYYCARSKGNYFYAMDYWGQGTLVTVSSGGG GSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTISCRASESVDSHGTSFMHWYQQKPGKSPKFLIYRASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQSNEDPPTFGGGTKVEIK SEQ ID NO: 19 Final humanized version of the scFv gene: >> Humanized scFv-2_polypeptide GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAAGGTGAGCTGCAAGGCCAGCGGCTACAGCTTCACCGGCTACTACATGCACTGGGTGAGGCAGGCCAGCGGCAAGGGCCTGGAGTGGATCGGCAGGGTGAACCCCAACAGCGGCGGCACCAGCTACAACCAGAAGTTCAAGGACAGGTTCACCATCAGCAGGGACAAGAGCATCAGCACCCTGTACCTGCAGATGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAGCAAGGGCAACTACTTCTACGCCATGGACTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGACATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACCATCAGCTGCAGGGCCAGCGAGAGCGTGGACAGCCACGGCACCAGCTTCATGCACTGGTACCAGCAGAAGCCCGGCAAGAGCCCCAAGTTCCTGATCTACAGGGCCAGCAACCTGGAGAGCGGCATCCCCAGCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGAGGACTTCGCCATCTACTACTGCCAGCAGAGCAACGAGGACCCCCCCACCTTCGGCGGCGGCACCAAGGTGGAGATCAAG Sequence number: 20 OKT8 heavy chain: (anti-CD8 mAb sequence): tttgaggtccagctgcagcagtctggggcagagcttgtgaagccaggggcctcagtcaagttgtcctgcacagcttctggcttcaacattaaagacacctatatacacttcgtgaggcagaggcctgaacagggcctggagtggattggaaggattgatcctgcgaat gataatactttatatgcctcaaagttccagggcaaggccactataacagcagacacatcatccaacacagcctacatgcacctctgcagcctgacatctggggacactgccgtctattactgtggtagaggttatggttactacgtatttgaccacttgggccaaggc SEQ ID NO: 21 OKT8 Heavy Chain: (Anti-CD8 mAb sequence):>H1 CDR is highlighted FEVQLQQSGAELVKPGASVKLSCTASGFNIKDTYIHFVRQRPEQGLEWIGRIDPANDNTLYASKFQGKATITADTSSNTAY MHLCSLTSGDTAVYYCGRGYGYYVFDHLGQG SEQ ID NO: 22 OKT8 Heavy Chain: (Anti-CD8 mAb sequence):>H3 tntcaggtgcagctgaagcagtctggggcagagcttgtgaagccaggggcctcagtcaagttgtcctgcacagcttctggcttcaacattaaagacacctatatacacttcgtgaggcagaggcctgaacagggcctggagtggattggaaggattgatcctgcgaatgataat actttatatgcctcaaagttccagggcaaggccactataacagcagacacatcatccaacacagcctacatgcacctctgcagcctgacatctggggacactgccgtctattactgtggtagaggttatggttactacgtatttgaccactggggccaaggcaccactctcaca SEQ ID NO: 23 OKT8 Heavy Chain: (Anti-CD8 mAb sequence):>H3 CDR is highlighted XQVQLKQSGAELVKPGASVKLSCTASGFNIKDTYIHFVRQRPEQGLEWIGRIDPANDNTLYASKFQGKATITADTSSNTAYMHLCSLTSGDTAVYYCGRGYGYYVFDHWGQGTTLT SEQ ID NO: 24 OKT8 Heavy Chain: (Anti-CD8 mAb sequence):>H6 tttgaggtccagctgcagcagtctggggcagagcttgtgaagccaggggcctcagtcaagttgtcctgcacagcttctggcttcaacattaaagacacctatatacacttcgtgaggcagaggcctgaacagggcctggagtggattggaaggattgatcctgcgaatgataat actttatatgcctcaaagttccagggcaaggccactataacagcagacacatcatccaacacagcctacatgcacctctgcagcctgacatctggggacactgccgtctattactgtggtagaggttatggttactacgtatttgaccactggggccaaggcaccactctcaca SEQ ID NO: 25 OKT8 Heavy Chain: (Anti-CD8 mAb sequence):>H6 CDR is highlighted FEVQLQQSGAELVKPGASVKLSCTASGFNIKDTYIHFVRQRPEQGLEWIGRIDPANDNTLYASKFQGKATITADTSSNTAYMHLCSLTSGDTAVYYCGRGYGYYVFDHWGQGTTLT SEQ ID NO: 26 OKT8 Heavy Chain: (Anti-CD8 mAb sequence):>H7 tcaggtccaactgcagcagcctggggcagagcttgtgaagccaggggcctcagtcaagttgtcctgcacagcttctggcttcaacattaaagacacctatatacacttcgtgaggcagaggcctgaacagggcctggagtggattggaaggattgatcctgcgaatgataatactttatatgcctcaaagttccagggcaaggccactataacagcagacacatcatccaacacagcctacatgcacctctgcagcctgacatctggggacactgccgtctattactgtggtagaggttatggttactacgtatttgaccactggggccaaggcaccactctcacat Sequence number: 27 OKT8 heavy chain: (anti-CD8 mAb sequence): >H7 The CDRs are highlighted QVQLQQPGAELVKPGASVKLSCTASGFNIKDTYIHFVRQRPEQGLEWIGRIDPANDNTLYASKFQGKATITADTSSNTAYMHLCSLTSGDTAVYYCGRGYGYYVFDHWGQGTTLT Sequence number: 28 OKT8 light chain: (anti-CD8 mAb sequence): >K4 GACATTGTGCTGACCCAATCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGGAGCTTACACGTTCGGAGGGGGACCAAGC SEQ ID NO: 29 OKT8 light chain: (anti-CD8 mAb sequence):>K4 CDR is highlighted DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELTRSEGDQ SEQ ID NO: 30 OKT8 light chain: (anti-CD8 mAb sequence):>K6 GATATTGTGCTAACTCAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACT CCTCATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTACTGTCAGCACATTAGGGAGCTTACACG SEQ ID NO: 31 OKT8 light chain: (anti-CD8 mAb sequence):>K6 CDR is highlighted DIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHIRELT SEQ ID NO: 32 OKT8 Light chain: (anti-CD8 mAb sequence):>K8 GACATCCAGCTGACTCAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAGAGGGCCACCATCTCATACAGGGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATGCACTGGAACCAACAGAAACCAGGACAGCCACCCAGACTCCTC ATCTATCTTGTATCCAACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCTGACCTATTAGCTGTCAGCACATTATGGGAGCTTACACGTTCGG SEQ ID NO: 33 OKT8 Light chain: (anti-CD8 mAb sequence):>K8 CDR is highlighted DIQLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGSGTDFTLNIHPVEEEDAADLLAVSTLWELTRS SEQ ID NO: 34 CD8 BiTE accggt atg gat atc gag ctg acc cag agc cct agc agc ctg gcc gtg tca ctg ggc cag aga gcc acc atc agc tgc aga gcc tcc gag agc gtg gat agc cac ggc acc agc ctg atg cac tgg tat cag cag aag ccc ggc cag ccc ccc aag ttc ctg atc tac cgg gcc agc aac ctg gaa agc ggc atc ccc gcc aga ttt tcc ggc agc ggc agc aga acc gac ttc acc ctg acc atc aac ccc gtg gag aca gac gac gtg gcc atc tac tac tgc cag cag agc aac gag gac cct ccc acc ttt ggc gga ggc acc aag ctg gaa ctg aag gag ggc gga gga agc gga ggg gga gga tct ggc gga ggc ggc agc gcc cag gtg aag ctg cag cag agc ggc cct gat ctg gtg aag cct ggc gcc agc gtg aag atc agc tgc aag gcc agc ggc tac agc ttc acc ggc tac tac atg cac tgg gtg aaa cag agc cac ggc aag agc ctg gaa tgg atc ggc aga gtg aac ccc aat agc ggc ggc acc agc tac aac cag aag ttc aag gac aag gcc atc ctg acc gtg gac aag agc agc agc acc gcc tac atg gaa ctg cgg agc ctg acc agc gag gac agc gcc gtg tac tac tgc gcc cgg tcc aag ggc aac tac ttc tac gcc atg gac tac tgg ggc cag ggc acc acc gtg acc gtg tct agc agcggc ggc ggc gga agc gaa gtg cag ctg cag cag tcc gga gca gaa ctg gtg aaa ccc gga gcc agt gtg aag ctg agc tgt aca gcc tcc ggc ttt aat atc aag gac acc tac atc cac ttc gtg cgc caa cgg cca gaa cag ggt ctg gag tgg att ggc agg atc gat cca gca aat gat aac acc ctg tac gca agc aaa ttt cag ggc aaa gcc acg ata acc gcc gat aca tct agt aat acg gct tac atg cac ctc tgc tcc ctg act tcc ggg gac acc gcc gtg tat tat tgc ggg cgc gga tac ggt tac gtg ttc gat cat tgg ggt cag ggc acc ctc aca gtc tcc agt gca gga ggc gga ggt agt gga ggc gga ggc tct ggc ggt ggc ggg tca gac ata gtg ctg aca cag tct ccc gcc agt ctg gca gtg agc ctt ggc cag agg gct aca att tcc tat agg gcg tct aaa tcc gtt agc act tca ggt tac tct tat atg cac tgg aac cag aag cct ggt cag ccc agg ctt ctt att tac ctg gtc agc aat ctc gag tct ggc gtg ccc gct aga ttt tcc ggc agc ggg agt ggg act gac ttc act ctg aac atc cac cca gtg gag gaa gag gat gcc gca acc tac tat tgt cag cat atc cgg gaa ttg acc aga tca gag ggc gga cct tcc tgg aag gag cag aag ctg att agc gaggaa gat ctg gat tat aag gac gat gac aaa tga gaa ttc sequence number: 35 CD8 BiTE T GMDIELTQSPSSLAVSLGQRATISCRASESVDSHGTSLMHWYQQKPGQPPKFLIYRASNLESGIPARFSGSGSRTDFTLTINPVETDDVAIYYCQQSNEDPPTFGGGTKLELKEGGGSGGGGSGGGGSA QVKLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSHGKSLEWIGRVNPNSSGGTSYNQKFKDKAILTVDKSSSTAYMELRSLTSEDSAVYYCARSKGNYFYAMDYWGQGTTVTVSSSSGGGGSEVQL QQSGAELVKPGASVKLSCTASGFNIKDTYIHFVRQRPEQGLEWIGRIDPANDNTLYASKFQGKATITADTSSNTAYMHLCSLTSGDTAVYYCGRGYGYVFDHWGQGTTLTVSSAGGGGSGGGGSGGGSDIVLTQSPASLAVSLGQRATISYRASKSVSTSGYSYMHWNQQKPGQPPRLLIYLVSNLESGVPARFSGSGTDFTLNIHPVEEDAATYCQHIRELTRSEGPSWKEQKLISEEDLDDYKDDDDK-EF sequence number: 36 CD3 BiTE accggtatg gat atc gag ctg acc cag agc cct agc ctg gcc gtg tca ctg ggc cag aga gcc acc atc agc tgc aga gcc tcc gag agc gtg gat agc cac ggc acc agc ctg atg cac tgg tat cag cag aag ccc ggc cag ccc ccc aag ttc ctg atc tac cgg gcc agc aac ctg gaa agc ggc atc ccc gcc aga ttt tcc ggc agc ggc agc aga acc gac ttc acc ctg acc atc aac ccc gtg gag aca gac gac gtg gcc atc tac tac tgc cag cag agc aac gag gac cct ccc acc ttt ggc gga ggc acc aag ctg gaa ctg aag gag ggc gga gga agc gga ggg gga gga tct ggc gga ggc ggc agc gcc cag gtg aag ctg cag cag agc ggc cct gat ctg gtg aag cct ggc gcc agc gtg aag atc agc tgc aag gcc agc ggc tac agc ttc acc ggc tac tac atg cac tgg gtg aaa cag agc cac ggc aag agc ctg gaa tgg atc ggc aga gtg aac ccc aat agc ggc ggc acc agc tac aac cag aag ttc aag gac aag gcc atc ctg acc gtg gac aag agc agc agc acc gcc tac atg gaa ctg cgg agc ctg acc agc gag gac agc gcc gtg tac tac tgc gcc cgg tcc aag ggc aac tac ttc tac gcc atg gac tac tgg ggc cag ggc acc acc gtg acc gtg tct agc agc ggc ggcggc gga agc gag gtt cag ctg gtg gag tct ggc ggt ggc ctg gtg cag cca ggg ggc tca ctc cgt ttg tcc tgt gca gct tct ggc tac tcc ttt acc ggc tac act atg aac tgg gtg cgt cag gcc cca ggt aag ggc ctg gaa tgg gtt gca ctg att aat cct tat aaa ggt gtt tcc acc tat aac cag aaa ttc aag gat cgt ttc acg ata tcc gta gat aaa tcc aaa aac aca gcc tac ctg caa atg aac agc ctg cgt gct gag gac act gcc gtc tat tat tgt gct aga agc gga tac tac ggc gat agc gac tgg tat ttt gac gtc tgg ggt caa gga acc ctg gtc acc gtc tcc tcg ggt gga ggc ggt tca ggc gga ggt ggc tct ggc ggt ggc gga tcg gat atc cag atg acc cag tcc ccg agc tcc ctg tcc gcc tct gtg ggc gat agg gtc acc atc acc tgt cgt gcc agt cag gac atc cgt aat tat ctc aac tgg tat caa cag aaa cca gga aaa gct ccg aaa cta ctg att tac tat acc tcc cgc ctg gag tct gga gtc cct tct cgc ttc tct ggt tct ggt tct ggg acg gat tac act ctg acc atc agc agt ctg caa ccg gag gac ttc gca act tat tac tgt cag caa ggt aat act ctg ccg tgg acg ttc gga cag ggc acc aag gtg gag atc aaa gag cag aagctg att agc gag gaa gat ctg gat tat aag gac gac gat gac aaa tga gaa ttc SEQ ID NO: 37 CD3 BiTE T.G. MDIELTQSPSSLAVSLGQRATISCRASESVDSHGTSLMHWYQQKPGQPPKFLIYRASNLESGIPARFSGSGSRTDFTLTINPVETDDVAIYYCQQSNEDPPTFGGGTKLELKEGGGSGGGGSGGGGSAQ VKLQQSGPDLVKPGASVKISKASGYSFTGYYMHWVKQSHGKSLEWIGRVNPNSGGTSYNQKFKDKAILTVDKSSSTAYMELRSLTSEDSAVYYCARSKGNYFYAMDYWGQGTTVTVSSSGGGGSEVQLV ESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSGGGGGSGGGGSGGG GSDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKEQKLISEEDLDYKDDDDK-EF SEQ ID NO: 38 FLAG tag DYKDDDDK SEQ ID NO: 39 Myc tag EQKLISEEDL SEQ ID NO: 40 Heavy chain sequence Color scheme: signal peptide-VH-CH (human IgG1) TGATTCTAGA is a stop codon SEQ ID NO: 41 Amino acid sequence: EVQLVESGGGLVQPGGSLRLSCKASGYSFTGYYMHWVRQAPGKGLEWIGRVNPNSGGTSYNQKFKDRATLSVDNSKNTAYLQMNSLRAEDTAVYYCARSKGNYFYAMDYWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO: 42 Light chain sequence Color scheme: signal peptide-VL-CL (human kappa) TGATTCTAGA is a stop codon GCGGCCGCAAACTACAAGACAGACTTGCAAAAGAAGGCATGCACAGCTCAGCACTGCTCTGTTGCCTGGTCCTCCTGACTGGGGTGAGGGCCGACATTCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCAGCGTGGGAGACAGAGTGACCATCACCTGCAGAGCCAGCGAGAGCGTGGACAGCCATG GCACCTCCTTTATGCACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAATTCCTGATTTACAGAGGCCAGCAACCTGGAGAGCGGCATCCCCTCAAGATTCTCAGGCAGCGAAGCGGAACCGACTTCACACTGACTATCAGCAGCGTGCAGCCCGAAGATTTTGCTGTGGTACTACTGCCAGCAGAGCA ACGAAGATCCTCCTACCTTCGGGGCGGCACTAAGGTGGAGATCAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCC AATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGGCGAAGTCACCCATCAGGGCCTGAGTTCGCCCGTCACAAAGAGCTTCAAACAGGGGAGAGTGTTGATTCTAGA SEQ ID NO: 43 amino acid sequence DIQMTQSPSSLSASVGDRVTITCRASESVDSHGTSFMHWYQQKPGKAPKFLIYRASNLESGIPSRFSGSGSGTDFTLTISSVQPEDFAVYYCQQSNEDPPTFGGGTKVE IKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 44 scFv against HERV-K MAP (anti-HERV-K mAb sequence) ATGGCCCAGGTGCAACTGCAGCAGTCAGGGGCTGAGCTTGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCTGGCTACACCTTCACCAGCTACTGGATAACCTGGGTGAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATTGGAGATATTTATCCTGGTAGTGGTAGTACTAACTACAATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGATGGCGGGACGGGTACTATGCTATGGACTACTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAAGTGAAGGCGGTTCAGGCGGAGGTTGCTCTGGCGGTGGCGGATCGGACATCGAGCTCACTCAGTCTCCAACCACCATGGCTGCATCTCCCGGGGAGAAGATCACTATCACCTGCAGTGCCAGCTCAAGTATAAGTTCCAATTACTTGCATTGGTATCAGCAGAAGCCAGGATTCTCCCCTAAACTCTTGATTTATAGGACATCCAATCTGGCTTCTGGAGTCCCAGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATTGGCACCATGGAAGCTGAAGATGTTGCCACTTACTACTGCCAGCAGGGTAGTAGTATACCATTCACGTTCGGCTCGGGGACGAAGTTGGAGCTGAAACGGGCGGGCCGCAGGTGCGCCGGTGCCGTATCCG Accession number: 45 scFv against the MAP of HERV-K (sequence of anti-HERV-K mAb) MAQVQLQQSGAELVKPGASVKMSCKASGYTFTSYWITWVKQRPGQGLEWIGDIYPGSGSTNYNEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCARWRDGYYAMDYWGQGTTVTVSSSEGGSG GGCSGGGGSDIELTQSPTTMAASPGEKITITCSASSSISSNYLHWYQQKPGFSPKLLIYRTSNLASGVPARFSGSGSGTSYSLTIGTMEAEDVATYYCQQGSSIPFTFGSGTKLELKRAGRRCAGAVS SEQ ID NO: 46 Human germline sequences near the CDR boundaries of humanized anti-HERV-K antibodies VRQAPGKGLEW SEQ ID NO: 47 Human germline sequences near the CDR boundaries of humanized anti-HERV-K antibodies LQMNSLRAEDTAVYYC SEQ ID NO: 48 Humanized CD8 Heavy Chain CDR is highlighted GAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCTACAGTGAAAATCTCCTGCAAGGTTTCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGCAACAGGCCCCTGGAAAAGGGCTTGAGTGGATGGGAAGGATTGATCCTGCGAATGAT AATACTTTATACGCAGAGAAGTTCCAGGGCAGAGTCACCATAACCGCGGACACGTCCTACAGACACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGGTAGAGGTTATGGTTACTACGTATTTGACCACTGGGGCCAAGGCACC SEQ ID NO: 49 Humanized CD8 Heavy Chain CDR is highlighted EVQLVQSGAEVKKPGATVKISCKVSGFNIKDTYMHWVQQAPGKGLEWMGRIDPANDNTLYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCGRGYGYYVFDHWGQGT SEQ ID NO: 50 Humanized CD8 light chain The CDRs are highlighted. GACATTGTGCTGACCCAGTCTCCAGCCTCCTTGGCCGTGTCTCCAGGACAGAGGGCCACCATCACCTGCAGAGCCAGCAAAAGTGTCAGTACATCTGGCTATAGTTATATTCACTGGTATCAGCAGAAACCAGGACAACCTCCTAAACTCCTG ATTTACCTTGTATCCAATAAAGACACTGGGGTCCCAGCCAGGTTCAGCGGCAGTGGGTCTGGGACCGATTTCACCCTCACAATTAATCCTGTGGAAGCTAATGATACTGCTAAATTATTAGCTGTCAGCACATTATGGGAGCTTACACGTCGG SEQ ID NO: 51 Humanized CD8 light chain The CDRs are highlighted. DIVLTQSPASLAVSPGQRATICRASKSVSTSGYSYIHWYQQKPGQPPKLLIYLVSNKDTGVPARFSGSGSGTDFTLTINPVEANDTAKLLAVSTLWELTRR SEQ ID NO: 52 CDR sequences GYSFTGYY SEQ ID NO: 53 CDR sequences VNPNSGGT SEQ ID NO: 54 CDR sequences ARSKGNYFYAMDY SEQ ID NO: 55 CDR sequences ASESVDSHGTSF SEQ ID NO: 56 CDR sequences RASN SEQ ID NO: 57 CDR sequences QQSNEDPPT
Claims
1. 1. An isolated human endogenous retrovirus-K (HERV-K) antagonist antibody that binds to a HERV-K envelope protein, comprising: (a) a humanized or human framework region; (b) a heavy chain variable region (HCVR) comprising the CDR sequences GYSFTGYY (SEQ ID NO: 52), VNPNSGGT (SEQ ID NO: 53), and ARSKGNYFYAMDY (SEQ ID NO: 54); (c) a light chain variable region (LCVR) comprising the CDR sequences ASESVDSHGTSF (SEQ ID NO: 56), RASN (SEQ ID NO: 56), and QQSNEDPPT (SEQ ID NO: 57); (d) An antagonist antibody characterized by binding to the full-length HERV-K envelope SU domain.
2. The antibody described in claim 1, further comprising a sequence near the CDR boundary selected from the group consisting of VRQAPGKGLEW (sequence number: 46) and LQMNSLRAEDTAVYYC (sequence number: 47).
3. The antibody according to claim 1, characterized in that the antibody is a HUM1 antibody.
4. The antibody according to claim 1, characterized in that the antibody is a hu6H5 antibody.
5. 2. The antibody of claim 1 for use in reducing tumor growth.
6. The antibody described in claim 1, characterized in that it is used in suppressing metastasis to the lungs, lymph nodes, or other organs.
7. An isolated nucleic acid comprising a nucleotide sequence encoding the HCVR, LCVR, or a combination thereof of claim 1.
8. An expression vector comprising the nucleic acid of claim 7.
9. A host cell transformed with the expression vector of claim 8.
10. 13. A method for treating cancer in a mammal, comprising administering a therapeutically effective amount of the antibody of claim 1 to a mammal in need thereof.
11. 11. The method of claim 10, wherein the antibody is conjugated to the cytotoxic agent, auristatin, or a functional peptide analog or derivative thereof via a linker.
12. 11. The method of claim 10, wherein the cancer is selected from the group consisting of melanoma, chronic lymphocytic leukemia, breast cancer, pancreatic cancer, head and neck cancer, ovarian cancer, cervical cancer, colorectal cancer, testicular cancer, gastric cancer, renal cancer, endometrial cancer, uterine cancer, bladder cancer, prostate cancer, esophageal cancer, liver cancer, and non-small cell lung cancer.
13. A humanized antibody for use in a CAR T, CAR NK, or BiTE assay.
14. A humanized antibody for use in a CAR T, CAR NK, or BiTE assay used to develop a CAR T, CAR NK, or BiTE.
15. 1. An isolated antibody that binds to human CD3 T cells or CD8 T cells, (a) a heavy chain variable region (HCVR) comprising the CDR sequences from SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27; (b) an antibody comprising a light chain variable region (LCVR) comprising the CDR sequences from SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO:
33.
16. A BiTE that targets T cell CD3 or CD8 and a humanized scFv against a tumor-associated antigen, HERV-K, comprising an antibody that targets either CD3 or CD8 and HERV-K.
17. T cells expressing lentiviral CAR expression vectors carrying humanized or fully human HERV-K scFv.
18. A humanized single-chain variable region (scFv) antibody capable of binding to an antigen generated from recombinant HERV-K Env surface fusion protein (KSU) and to lysates of cancer cells expressing HERV-K Env protein.
19. A CAR generated from the humanized scFv of claim 18.
20. A method of using HERV-K immune checkpoint inhibitors to block the immunosuppressive domain (ISD).
21. The method of claim 20, characterized in that the HERV-K immune checkpoint inhibitor is selected from the group consisting of monoclonal antibodies and drugs that target the ISD of HERV-K.
Citation Information
Patent Citations
Endogenous retrovirus up-regulated in prostate cancer
US20060275747A1
HERV-k antigens, antibodies, and methods
US20090297530A1
HERV-k antigens, antibodies, and methods
US20140099324A1
